<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1444" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1444/" /><meta name="ncbi_pagename" content="Hemophagocytic Lymphohistiocytosis, Familial - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hemophagocytic Lymphohistiocytosis, Familial - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hemophagocytic Lymphohistiocytosis, Familial" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/01/17" /><meta name="citation_author" content="Kejian Zhang" /><meta name="citation_author" content="Alexandra H Filipovich" /><meta name="citation_author" content="Judith Johnson" /><meta name="citation_author" content="Rebecca A Marsh" /><meta name="citation_author" content="Joyce Villanueva" /><meta name="citation_pmid" content="20301617" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1444/" /><meta name="citation_keywords" content="Familial Erythrophagocytic Lymphohistiocytosis" /><meta name="citation_keywords" content="FHLH" /><meta name="citation_keywords" content="FHLH" /><meta name="citation_keywords" content="Familial Erythrophagocytic Lymphohistiocytosis" /><meta name="citation_keywords" content="Perforin-1" /><meta name="citation_keywords" content="Protein unc-13 homolog D" /><meta name="citation_keywords" content="Syntaxin-11" /><meta name="citation_keywords" content="Syntaxin-binding protein 2" /><meta name="citation_keywords" content="PRF1" /><meta name="citation_keywords" content="STX11" /><meta name="citation_keywords" content="STXBP2" /><meta name="citation_keywords" content="UNC13D" /><meta name="citation_keywords" content="Hemophagocytic Lymphohistiocytosis, Familial" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hemophagocytic Lymphohistiocytosis, Familial" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Kejian Zhang" /><meta name="DC.Contributor" content="Alexandra H Filipovich" /><meta name="DC.Contributor" content="Judith Johnson" /><meta name="DC.Contributor" content="Rebecca A Marsh" /><meta name="DC.Contributor" content="Joyce Villanueva" /><meta name="DC.Date" content="2013/01/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1444/" /><meta name="description" content="Familial hemophagocytic lymphohistiocytosis (FHL) is characterized by proliferation and infiltration of hyperactivated macrophages and T-lymphocytes manifesting as acute illness with prolonged fever, cytopenias, and hepatosplenomegaly. Onset is typically within the first months or years of life and, on occasion, in utero, although later childhood or adult onset is more common than previously suspected. Neurologic abnormalities may be present initially or may develop later; they may include increased intracranial pressure, irritability, neck stiffness, hypotonia, hypertonia, convulsions, cranial nerve palsies, ataxia, hemiplegia, quadriplegia, blindness, and coma. Rash and lymphadenopathy are less common. Other findings include liver dysfunction and bone marrow hemophagocytosis. The median survival of children with typical FHL, without treatment, is less than two months; progression of hemophagocytic lymphohistiocytosis and infection account for the majority of deaths in untreated individuals." /><meta name="og:title" content="Hemophagocytic Lymphohistiocytosis, Familial" /><meta name="og:type" content="book" /><meta name="og:description" content="Familial hemophagocytic lymphohistiocytosis (FHL) is characterized by proliferation and infiltration of hyperactivated macrophages and T-lymphocytes manifesting as acute illness with prolonged fever, cytopenias, and hepatosplenomegaly. Onset is typically within the first months or years of life and, on occasion, in utero, although later childhood or adult onset is more common than previously suspected. Neurologic abnormalities may be present initially or may develop later; they may include increased intracranial pressure, irritability, neck stiffness, hypotonia, hypertonia, convulsions, cranial nerve palsies, ataxia, hemiplegia, quadriplegia, blindness, and coma. Rash and lymphadenopathy are less common. Other findings include liver dysfunction and bone marrow hemophagocytosis. The median survival of children with typical FHL, without treatment, is less than two months; progression of hemophagocytic lymphohistiocytosis and infection account for the majority of deaths in untreated individuals." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1444/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="warning" content="This publication is provided for historical reference only and the information may be out of date." /><meta name="bk-non-canon-loc" content="/books/n/gene/hlh/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1444/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">.main-content {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/css/bookshelf/2.22/img/archive.png);background-size: auto, contain; padding:0 0 0 3em }</style><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CA31DE0423FD100000000026E00F5.m_13" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="messagearea bk_noprnt" style="margin-bottom:1.3846em "><ul class="messages"><li class="warn icon"><span class="icon">This publication is provided for historical reference only and the information may be out of date.</span></li></ul></div><div class="bk_prnt"><p style="color:red;"><strong>This publication is provided for historical reference only and the information may be out of date.</strong></p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1444_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1444_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hartsfield/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hemo-a/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1444_"><span class="title" itemprop="name">Hemophagocytic Lymphohistiocytosis, Familial</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Erythrophagocytic Lymphohistiocytosis, FHLH</div><p class="contrib-group"><span itemprop="author">Kejian Zhang</span>, MD, MBA, <span itemprop="author">Alexandra H Filipovich</span>, MD, <span itemprop="author">Judith Johnson</span>, MS, <span itemprop="author">Rebecca A Marsh</span>, MD, and <span itemprop="author">Joyce Villanueva</span>, MT, MBA.</p><a data-jig="ncbitoggler" href="#__NBK1444_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1444_ai__"><div class="contrib half_rhythm"><span itemprop="author">Kejian Zhang</span>, MD, MBA<div class="affiliation small">Associate Professor of Pediatrics, Division of Human Genetics<br />Cincinnati Children's Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@gnahz.naijek" class="oemail">gro.cmhcc@gnahz.naijek</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Alexandra H Filipovich</span>, MD<div class="affiliation small">Professor, Division of Bone Marrow Transplant and Immune Deficiency<br />Cincinnati Children<br />s Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@hcivopilif.asil" class="oemail">gro.cmhcc@hcivopilif.asil</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Judith Johnson</span>, MS<div class="affiliation small">Genetic Counselor and Project Manager<br />Division of Human Genetics<br />Cincinnati Children's Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@nosnhoj.ahtiduj" class="oemail">gro.cmhcc@nosnhoj.ahtiduj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Rebecca A Marsh</span>, MD<div class="affiliation small">Assistant Professor, Division of Bone Marrow Transplant and Immune Deficiency<br />Cincinnati Children's Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@hsram.acceber" class="oemail">gro.cmhcc@hsram.acceber</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Joyce Villanueva</span>, MT, MBA<div class="affiliation small">Research and Development Coordinator<br />Immunodeficiency and Histiocytosis Program<br />Cincinnati Children's Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@aveunalliv.ecyoj" class="oemail">gro.cmhcc@aveunalliv.ecyoj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 22, 2006</span>; Last Update: <span itemprop="dateModified">January 17, 2013</span>.</p><p><em>Estimated reading time: 36 minutes</em></p></div><div class="body-content whole_rhythm" itemprop="text"><div id="hlh.Summary" itemprop="description"><h2 id="_hlh_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Familial hemophagocytic lymphohistiocytosis (FHL) is characterized by proliferation and infiltration of hyperactivated macrophages and T-lymphocytes manifesting as acute illness with prolonged fever, cytopenias, and hepatosplenomegaly. Onset is typically within the first months or years of life and, on occasion, in utero, although later childhood or adult onset is more common than previously suspected. Neurologic abnormalities may be present initially or may develop later; they may include increased intracranial pressure, irritability, neck stiffness, hypotonia, hypertonia, convulsions, cranial nerve palsies, ataxia, hemiplegia, quadriplegia, blindness, and coma. Rash and lymphadenopathy are less common. Other findings include liver dysfunction and bone marrow hemophagocytosis. The median survival of children with typical FHL, without treatment, is less than two months; progression of hemophagocytic lymphohistiocytosis and infection account for the majority of deaths in untreated individuals.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of FHL is made based on the presence of clinical criteria and is confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Five disease subtypes (FHL1, FHL2, FHL3, FHL4, and FHL5) are described. Four genes in which pathogenic variants are causative have been identified: <i>PRF1</i> (FHL2), <i>UNC13D</i> (FHL3), <i>STX11</i> (FHL4), and <i>STXBP2</i> (FHL5).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Antibiotics or antiviral agents are used to treat or prevent infections that may have triggered the exaggerated inflammatory response. Individuals suspected of having FHL or diagnosed with FHL are treated with chemotherapy and immunotherapy to achieve clinical stability prior to allogeneic hematopoietic cell transplantation (HCT).</p><p><i>Prevention of primary manifestations:</i> Allogeneic HCT is the only curative therapy and is undertaken as early in life as feasible in children with confirmed FHL.</p><p><i>Surveillance</i>: Following HCT, annual neuropsychological evaluation and regular follow up by a transplant specialist to monitor for late complications related to growth and hormone function is recommended.</p><p><i>Agents/circumstances to avoid</i>: Live vaccines; exposure to infections.</p><p><i>Evaluation of relatives at risk:</i> Molecular genetic testing of at-risk sibs for the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pathogenic variants enables consideration of presymptomatic bone marrow transplantation and timely treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>FHL is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the two pathogenic variants in the family are known.</p></div></div><div id="hlh.Diagnosis"><h2 id="_hlh_Diagnosis_">Diagnosis</h2><div id="hlh.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis (FHL), a cellular immunologic disorder resulting from genetic defects in cytotoxic cell function that lead to hyperactivation, proliferation, and infiltration of macrophages and T-lymphocytes, can be established if <b>1</b>
<b>and/or 2</b> is present:</p><p><b>1. Biallelic pathogenic variants</b> in any one of <i>PRF1</i>, <i>UNC13D</i> (also known as <i>MUNC13-4</i>), <i>STX11,</i> or <i>STXBP2</i></p><p><b>2. At least five of the eight following criteria</b> based on the guidelines of the <a href="https://www.histiocytesociety.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Histiocyte Society</a> [<a class="bk_pop" href="#hlh.REF.henter.2007.124">Henter et al 2007</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm">Prolonged fever (&#x0003e;7 days)</div></li><li class="half_rhythm"><div class="half_rhythm">Cytopenias affecting <b>two or three</b> of the three lineages in the peripheral blood:</div><ul><li class="half_rhythm"><div>Hemoglobin &#x0003c;90 g/L (for infants age &#x0003c;4 weeks: Hgb &#x0003c;100 g/L)</div></li><li class="half_rhythm"><div>Platelets &#x0003c;100x109/L</div></li><li class="half_rhythm"><div>Neutrophils &#x0003c;1.0x109/L</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Splenomegaly</div></li><li class="half_rhythm"><div class="half_rhythm">Hypertriglyceridemia and/or hypofibrinogenemia</div><ul><li class="half_rhythm"><div>Fasting triglycerides &#x02265;2.0 mmol/L or &#x0003e;3 SD of the normal value for age</div></li><li class="half_rhythm"><div>Fibrinogen &#x02264;1.5 g/L</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Hemophagocytosis. Non-malignant, mixed lymphohistiocytic accumulation in the reticuloendothelial system; the spleen, liver, lymph nodes, bone marrow, and CNS are most frequently involved.</div><div class="half_rhythm">Note: (1) Hemophagocytosis may not be apparent early in the course of the disease. (2) Hemophagocytosis is seen less often in the liver, where lymphocytic infiltration of the portal areas is typical [<a class="bk_pop" href="#hlh.REF.kapelari.2005.619">Kapelari et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Low or absent natural killer (NK) cell activity. This is common prior to and during active disease, as well as after remission following chemotherapy in a significant proportion of individuals with FHL. Normal or raised NK cell activity has also been observed in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, including those with <i>UNC13D</i> pathogenic variants [<a class="bk_pop" href="#hlh.REF.yamamoto.2004.763">Yamamoto et al 2004</a>, <a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al 2005</a>].</div><div class="half_rhythm">Note: (1) NK cell activity normative values are per local laboratory reference. (2) The number of circulating NK cells (CD56+/16+) is generally within normal limits. (3) In secondary (acquired or reactive) hemophagocytic lymphohistiocytosis (HLH), NK cell activity has been reported to normalize during remission [<a class="bk_pop" href="#hlh.REF.horne.2005b.658">Horne et al 2005b</a>, <a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Hyperferritinemia. Serum ferritin concentration &#x02265;500 &#x000b5;g/L (normal 10-290 &#x000b5;g/L)</div></li><li class="half_rhythm"><div class="half_rhythm">High plasma concentrations of soluble CD25 (soluble IL2R&#x003b1;); &#x02265;2400 U/mL</div><div class="half_rhythm">Note: (1) Normal range depends on test methodology used. (2) Results must be compared to age-matched controls.</div></li></ul><p>The presence of inflammatory cells in the spinal fluid in association with increased CSF protein and/or characteristic findings on brain MRI (including gross demyelination or failure of normal myelination during the first year of life, multifocal inflammation involving gray and white matter and intracranial bleeding, generalized atrophy, or brain edema are also highly suspicious for HLH [<a class="bk_pop" href="#hlh.REF.filipovich.2011.512">Filipovich 2011</a>] but are not part of the formal diagnostic criteria.</p><p>In addition, a positive family history of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs and/or parental <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> in a symptomatic individual supports the diagnosis of FHL.</p></div><div id="hlh.Testing"><h3>Testing</h3><p><b>Protein analysis</b></p><ul><li class="half_rhythm"><div>Perforin (the protein product of <i>PRF1</i>) analysis by flow cytometry:</div><ul><li class="half_rhythm"><div>In general, absent or markedly decreased perforin protein expression is highly likely to be associated with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants in <i>PRF1</i>.</div></li><li class="half_rhythm"><div>Of note, normal perforin protein expression may be associated with <i>PRF1</i> pathogenic variants because some <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants alter perforin protein function without significantly changing protein expression.</div></li><li class="half_rhythm"><div>If perforin protein expression is normal or increased, <i>UNC13D</i> or <i>STXBP2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be considered first.</div></li></ul></li><li class="half_rhythm"><div>Natural killer (NK) cell activity analysis:</div><ul><li class="half_rhythm"><div>Low or absent NK cell activity is an important biomarker in persons with FHL.</div></li><li class="half_rhythm"><div>Low or absent NK cell activity is usually observed in persons with confirmed <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PRF1</i>, <i>UNC13D</i>, <i>STXBP2</i> or <i>STX11</i> [<a class="bk_pop" href="#hlh.REF.sieni.2012a.29">Sieni et al 2012a</a>].</div></li><li class="half_rhythm"><div>In secondary (acquired or reactive) hemophagocytic lymphohistiocytosis (HLH), NK cell activity may fluctuate over time [<a class="bk_pop" href="#hlh.REF.horne.2005b.658">Horne et al 2005b</a>, <a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al 2005</a>].</div></li></ul></li><li class="half_rhythm"><div>NK cell degranulation (CD107a) analysis:</div><ul><li class="half_rhythm"><div>NK cell degranulation can be quantified by measurement of upregulation of surface CD107a [<a class="bk_pop" href="#hlh.REF.bryceson.2007.1906">Bryceson et al 2007</a>].</div></li><li class="half_rhythm"><div>Defective CD107a surface expression in NK cells is a frequent finding in persons with <i>UNC13D</i> pathogenic variants (FHL3) and <i>STX11</i> pathogenic variants (FHL4), in contrast to healthy controls or persons with <i>PRF1</i> pathogenic variants (FHL2) [<a class="bk_pop" href="#hlh.REF.marcenaro.2006.2316">Marcenaro et al 2006</a>]. Individuals with pathogenic variants in <i>STXBP2</i> (FHL5) also have defective CD107a expression [<a class="bk_pop" href="#hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</a>].</div></li></ul></li><li class="half_rhythm"><div>Granzyme B initiates caspase-dependent and caspase-independent apoptotic killing of target cells.</div><ul><li class="half_rhythm"><div>In most types of HLH, including those caused by mutation of <i>PRF1</i> and <i>UNC13D</i> as well as secondary HLH, granzyme B ranges from increased to markedly increased.</div></li><li class="half_rhythm"><div>Increased amounts of granzyme B in persons with HLH do not necessarily indicate normal killing, but most likely indicate that the granules housing the granzymes are not able to mobilize normally.</div></li></ul></li><li class="half_rhythm"><div>Soluble IL2R is an indicator of prolonged activation of T cells.</div><ul><li class="half_rhythm"><div>As the IL-2 receptor (CD25) forms on the surface of T cells during activation, increasing density of the receptor causes shedding into the plasma.</div></li><li class="half_rhythm"><div>This soluble form of the receptor is useful as a diagnostic criterion of any of the forms of HLH and for monitoring reoccurrence of the disease.</div></li><li class="half_rhythm"><div>Elevated soluble IL-2 receptor levels do not differentiate between primary (genetic) and secondary HLH.</div></li><li class="half_rhythm"><div>It is expected for children to have different expression of CD25 and thus the soluble form of the IL2R in plasma at different ages. Therefore, when interpreting results in children, age-based reference ranges should be used.</div></li></ul></li><li class="half_rhythm"><div>Serum ferritin concentration is a marker for generalized inflammation.</div><ul><li class="half_rhythm"><div>It is, however, markedly elevated in the majority of persons with HLH and is a very sensitive indicator of HLH when serum concentrations are markedly increased.</div></li><li class="half_rhythm"><div>Increased serum ferritin concentrations make no distinction between genetic and secondary HLH.</div></li></ul></li></ul><div id="hlh.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>Genes/loci.</b> Five loci (FHL1, FHL2, FHL3, FHL4, and FHL5) are associated with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis; the five disease subtypes are based on these loci (<a class="figpopup" href="/books/NBK1444/table/hlh.T.locus_names_genes_and_pathogenic_v/?report=objectonly" target="object" rid-figpopup="fighlhTlocusnamesgenesandpathogenicv" rid-ob="figobhlhTlocusnamesgenesandpathogenicv">Table 1</a>). Four genes have been identified and characterized: <i>PRF1</i> (FHL2), <i>UNC13D</i> (FHL3), <i>STX11</i> (FHL4), and <i>STXBP2</i> (FHL5).</p><div id="hlh.T.locus_names_genes_and_pathogenic_v" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Locus Names, Genes, and Pathogenic Variants Associated with Familial Hemophagocytic Lymphohistiocytosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.T.locus_names_genes_and_pathogenic_v/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.T.locus_names_genes_and_pathogenic_v_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Locus Name</th><th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of FHL</th><th id="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Identified</th></tr></thead><tbody><tr><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL1</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4 <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> Pakistani families&#x000a0;<sup>1</sup></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL2</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRF1</i></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-30%&#x000a0;<sup>2,&#x000a0;3</sup> worldwide<br />&#x0003e;50% in African American families&#x000a0;<sup>4</sup></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple distinctive pathogenic variants throughout entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a></td></tr><tr><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL3</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UNC13D</i><br />(<i>MUNC13-4</i>)</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~20%-30%&#x000a0;<sup>3,&#x000a0;5</sup> worldwide</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple distinctive pathogenic variants throughout entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> sites<br />Deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> &#x00026; large inversion also reported&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL4</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>STX11</i></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~20% of Turkish/Kurdish families&#x000a0;<sup>5,&#x000a0;7</sup><br />Biallelic pathogenic variants identified in other ethnic groups (at a low frequency)&#x000a0;<sup>8</sup></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 recurrent pathogenic variants identified in Turkish/Kurdish families<br />Other pathogenic variants identified in other populations</td></tr><tr><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL5</td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>STXBP2</i></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16% in Central Europeans, Turks, &#x00026; Saudis&#x000a0;<sup>9</sup><br />~20% in North Americans w/FHL&#x000a0;<sup>10</sup></td><td headers="hd_h_hlh.T.locus_names_genes_and_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple distinctive pathogenic variants throughout entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> sites</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hlh.TF.1.1"><p class="no_margin">Linkage analysis using homozygosity mapping in four <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> families of Pakistani descent with hemophagocytic lymphohistiocytosis (HLH) identified a <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> (FHL1) on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 9q21.3 22 [<a class="bk_pop" href="#hlh.REF.ohadi.1999.165">Ohadi et al 1999</a>]. No <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is causative has been identified at this locus.</p></div></dd><dt>2. </dt><dd><div id="hlh.TF.1.2"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.voskoboinik.2004.811">Voskoboinik et al [2004]</a></p></div></dd><dt>3. </dt><dd><div id="hlh.TF.1.3"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al [2005]</a></p></div></dd><dt>4. </dt><dd><div id="hlh.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al [2004]</a>, <a class="bk_pop" href="#hlh.REF.lee.2006.134">Lee et al [2006]</a></p></div></dd><dt>5. </dt><dd><div id="hlh.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.zur_stadt.2005.827">zur Stadt et al [2005]</a></p></div></dd><dt>6. </dt><dd><div id="hlh.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.meeths.2011.5783">Meeths et al [2011]</a></p></div></dd><dt>7. </dt><dd><div id="hlh.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.zur_stadt.2006.62">zur Stadt et al [2006]</a></p></div></dd><dt>8. </dt><dd><div id="hlh.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.marsh.2010b.134">Marsh et al [2010b]</a>; Weitzman, personal communication (2010)</p></div></dd><dt>9. </dt><dd><div id="hlh.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.zur_stadt.2009.482">zur Stadt et al [2009]</a></p></div></dd><dt>10. </dt><dd><div id="hlh.TF.1.10"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.johnson.2010">Johnson et al [2010]</a></p></div></dd></dl></div></div></div><p><b>Evidence for <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity.</b> Approximately 30% of individuals diagnosed with FHL do not have identified pathogenic variants in any of the four genes listed (see <a class="figpopup" href="/books/NBK1444/table/hlh.T.locus_names_genes_and_pathogenic_v/?report=objectonly" target="object" rid-figpopup="fighlhTlocusnamesgenesandpathogenicv" rid-ob="figobhlhTlocusnamesgenesandpathogenicv">Table 1</a>). <a class="bk_pop" href="#hlh.REF.m_nasch_.2005.165">M&#x000e9;nasch&#x000e9; et al [2005]</a> provide evidence that additional genetic loci may be responsible for FHL.</p><div id="hlh.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Familial Hemophagocytic Lymphohistiocytosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Locus Name / Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of FHL Attributed to Pathogenic Variants in Gene</th><th id="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL2 /<br /><i>PRF1</i></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-30%&#x000a0;<sup>3</sup><br />&#x0003e;50%&#x000a0;<sup>4</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">FHL3 /<br /><i>UNC13D</i></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-30%&#x000a0;<sup>3</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>7,&#x000a0;8</sup></td></tr><tr><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>9</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">253-kb inversion&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">FHL4 /<br /><i>STX11</i></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~20% in Turks/Kurds&#x000a0;<sup>10</sup><br />1% in North Americans&#x000a0;<sup>11</sup><br />5% in Central Europeans&#x000a0;<sup>10</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td></tr><tr><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>12</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exon- &#x00026; whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>&#x000a0;<sup>13</sup></td></tr><tr><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FHL5 /<br /><i>STXBP2</i></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~20% in North Americans&#x000a0;<sup>14</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_hlh.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hlh.TF.2.1"><p class="no_margin">See <a href="/books/NBK1444/#hlh.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hlh.TF.2.2"><p class="no_margin">See <a href="#hlh.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="hlh.TF.2.3"><p class="no_margin">Pathogenic variants in both <i>PRF1</i> and <i>UNC13D</i> have been identified with almost equal frequency (~20%-30%) in individuals of western European and Japanese descent [<a class="bk_pop" href="#hlh.REF.g_ransdotter_ericson.2001.590">G&#x000f6;ransdotter Ericson et al 2001</a>, <a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</a>, <a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al 2005</a>, <a class="bk_pop" href="#hlh.REF.lee.2006.134">Lee et al 2006</a>].</p></div></dd><dt>4. </dt><dd><div id="hlh.TF.2.4"><p class="no_margin">For individuals of African American descent [<a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</a>]</p></div></dd><dt>5. </dt><dd><div id="hlh.TF.2.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, partial-, whole-, or multigene deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="hlh.TF.2.6"><p class="no_margin">Sequence analysis and scanning of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> for pathogenic variants can have similar variant detection frequencies; however, variant detection rates for scanning may vary considerably between laboratories depending on the specific protocol used.</p></div></dd><dt>7. </dt><dd><div id="hlh.TF.2.7"><p class="no_margin">Single pathogenic variants have been identified in <i>PRF1</i> [Johnson, unpublished data (2012)], <i>UNC13D</i> [<a class="bk_pop" href="#hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</a>; Qian, personal communication (2012)], and <i>STXBP2</i> [Johnson, unpublished (2012)] in a minority of individuals with HLH. These data suggest that a second <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in (a) the other <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> not detectable by direct sequencing, or in (b) a different HLH-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> may be responsible for a minority of cases. Based on family studies, there is no evidence of a dominant model of disease in FHL2, FHL3, FHL4, or FHL5.</p></div></dd><dt>8. </dt><dd><div id="hlh.TF.2.8"><p class="no_margin">A deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been reported; this must be included in design of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> approach (see <a href="#hlh.Molecular_Genetics">Molecular Genetics</a>) [<a class="bk_pop" href="#hlh.REF.meeths.2011.5783">Meeths et al 2011</a>].</p></div></dd><dt>9. </dt><dd><div id="hlh.TF.2.9"><p class="no_margin">Targeted <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> specific for the breakpoints of the 253-kb inversion (see <a href="#hlh.Molecular_Genetics">Molecular Genetics</a>) [<a class="bk_pop" href="#hlh.REF.meeths.2011.5783">Meeths et al 2011</a>]</p></div></dd><dt>10. </dt><dd><div id="hlh.TF.2.10"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.rudd.2006.e14">Rudd et al [2006]</a>, <a class="bk_pop" href="#hlh.REF.zur_stadt.2006.62">zur Stadt et al [2006]</a></p></div></dd><dt>11. </dt><dd><div id="hlh.TF.2.11"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.marsh.2010a.1079">Marsh et al [2010a]</a></p></div></dd><dt>12. </dt><dd><div id="hlh.TF.2.12"><p class="no_margin">Testing that identifies deletions/duplications not readily detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA; methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>13. </dt><dd><div id="hlh.TF.2.13"><p class="no_margin">A whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <i>STX11</i> has been reported [<a class="bk_pop" href="#hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</a>].</p></div></dd><dt>14. </dt><dd><div id="hlh.TF.2.14"><p class="no_margin"><a class="bk_pop" href="#hlh.REF.johnson.2010">Johnson et al [2010]</a></p></div></dd></dl></div></div></div><p><b>Interpretation of test results</b></p><ul><li class="half_rhythm"><div>Some individuals with FHL have only one identified <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; it is possible that the second <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is mutated in the <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>, deeper in the introns in other non-coding regions of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, or is a large complex rearrangement and is thus undetectable by methods in current use. Alternately, a second pathogenic variant could be present in a different HLH-related gene for which clinical testing is not currently possible.</div></li><li class="half_rhythm"><div>Approximately 30% of North American individuals with FHL do not have pathogenic variants in <i>PRF1</i>, <i>UNC13D</i>, <i>STX11</i> or <i>STXBP2</i> [Johnson, unpublished data (2012)]; therefore, normal test results do not exclude the diagnosis of FHL.</div></li></ul></div></div><div id="hlh.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The recommended genetic workup of a person with HLH is complex and depends on the individual's race/ethnicity, immunologic test results, and clinical presentation, among other factors (see <a href="#hlh.GenotypePhenotype_Correlations">Genotype/Phenotype Correlations</a>). A <a href="https://www.cincinnatichildrens.org/service/h/hlh/clinical/test/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">testing algorithm</a> is available to assist clinicians in the prioritization of testing [<a class="bk_pop" href="#hlh.REF.jordan.2011.4041">Jordan et al 2011</a>].</p><p>No unique clinical findings distinguish between FHL2, FHL3, FHL4, and FHL5. However, immunologic testing may be useful in directing the genetic workup of a person with FLH (see <a href="#hlh.GenotypePhenotype_Correlations">Genotype/Phenotype Correlations</a> and <a href="https://www.cincinnatichildrens.org/service/h/hlh/clinical/test/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">testing algorithm</a>).</p><ul><li class="half_rhythm"><div class="half_rhythm"><i>PRF1</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> / scanning for pathogenic variants is generally performed first, as more than 80% of African Americans and 20% of North Americans of northern European background with FHL have at least one <i>PRF1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [Johnson, unpublished data (2012)].</div><div class="half_rhythm">Sequence analysis typically does not detect gross deletions (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>, multiexon, or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions), insertions, or some complex gene rearrangements. However, no gross deletions, insertions, or complex gene rearrangements have been identified in <i>PRF1</i> to date.</div></li><li class="half_rhythm"><div class="half_rhythm">In persons of northern European background, <i>UNC13D</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is generally performed next. <i>UNC13D</i> pathogenic variants are rare in African Americans. Sequencing of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> boundaries of <i>UND13D</i> including targeted analyses of the deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant and the large inversion should be performed.</div><div class="half_rhythm">Approximately 1%-2% of North Americans of northern European background have the deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant or the large inversion [Qian, personal communication (2012)].</div></li><li class="half_rhythm"><div class="half_rhythm"><i>STXBP2</i> pathogenic variants account for about 20% of pathogenic variants in North American persons with FHL and have been identified in all ethnic/racial groups tested [Johnson, unpublished data (2012)]. Therefore, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> for <i>STXBP2</i> is appropriate in any person with suspected FHL for whom <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>PRF1</i> and <i>UNC13D</i> is normal. Of note, no gross deletions, insertions, or complex rearrangements have been identified in <i>STXBP2</i> to date.</div></li><li class="half_rhythm"><div class="half_rhythm">Pathogenic variants in <i>STX11</i> account for about 1% of the pathogenic variants in North American individuals and about 5% of central European individuals with HLH. Sequence analysis or scanning of <i>STX11</i> for pathogenic variants should follow <i>PRF1, UNC13D</i>, and <i>STXBP2</i> variant analyses that do not identify at least one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. If <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> is normal, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>STX11</i> can be considered, as gross deletions have been reported in <i>STX11</i>. Pathogenic variants in <i>STX11</i> have been identified in most racial/ethnic groups [<a class="bk_pop" href="#hlh.REF.marsh.2010b.134">Marsh et al 2010b</a>].</div></li></ul><p>In symptomatic individuals not found to have pathogenic variants in <i>PRF1</i>, <i>UNC13D</i>, <i>STX11</i>, or <i>STXBP2</i>, sequencing of <i>RAB27A</i> for Griscelli syndrome type 2 (see <a href="#hlh.Differential_Diagnosis">Differential Diagnosis</a>) should be considered.</p><p>Note: Approximately 2%-3% of North American individuals with FHL have pathogenic variants in <i>RAB27A.</i> These individuals may not show evidence of partial albinism or other pigmentary abnormalities typically reported with Griscelli syndrome type 2 [Johnson, unpublished data (2012)].</p><p>In males with symptoms of HLH not found to have pathogenic variants in <i>PRF1</i>, <i>UNC13D</i>, <i>STX11,</i>
<i>STXBP2,</i> or <i>RAB27A</i>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>XIAP</i> (also known as <i>BIRC4</i>) and <i>SH2D1A</i> should be considered (see <a href="#hlh.Differential_Diagnosis">Differential Diagnosis</a>).</p><p><b>Carrier testing for at-risk relatives</b> requires prior identification of two pathogenic variants in the family.</p><p>Note: Carriers are heterozygotes for this <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder and are not at risk of developing the disorder.</p><p><b>Predictive testing</b> for at-risk asymptomatic sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> requires prior identification of two pathogenic variants in the family.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of two pathogenic variants in the family.</p></div></div><div id="hlh.Clinical_Characteristics"><h2 id="_hlh_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hlh.Clinical_Description"><h3>Clinical Description</h3><p>Symptoms of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis (FHL) are usually evident within the first months or years of life [<a class="bk_pop" href="#hlh.REF.aric_.1996.197">Aric&#x000f2; et al 1996</a>] and may even develop in utero [<a class="bk_pop" href="#hlh.REF.malloy.2004.458">Malloy et al 2004</a>]. However, symptomatic presentation throughout childhood and even into adulthood has been observed in some cases [<a class="bk_pop" href="#hlh.REF.aric_.1996.197">Aric&#x000f2; et al 1996</a>, <a class="bk_pop" href="#hlh.REF.allen.2001.499">Allen et al 2001</a>, <a class="bk_pop" href="#hlh.REF.clementi.2002.2266">Clementi et al 2002</a>, <a class="bk_pop" href="#hlh.REF.zhang.2011.5794">Zhang et al 2011</a>, <a class="bk_pop" href="#hlh.REF.sieni.2012b.e44649">Sieni et al 2012b</a>].</p><p>FHL usually presents in childhood as an acute illness with prolonged fever (&#x0003e;7 days), cytopenias, and hepatosplenomegaly. Rash and lymphadenopathy are less frequently observed. Liver dysfunction (elevated serum aminotransferase and bilirubin), neurologic dysfunction (irritability or lethargy, hypotonia or hypertonia, seizures, ataxia, and cranial nerve involvement presenting as nerve palsy and blindness), and bone marrow hemophagocytosis complete the typical presentation of the disorder.</p><p>Oftentimes, FHL is associated with documented infection, especially herpes viral infections [<a class="bk_pop" href="#hlh.REF.imashuku.2005.315">Imashuku et al 2005</a>] and leishmaniasis [<a class="bk_pop" href="#hlh.REF.filipovich.2011.512">Filipovich 2011</a>].</p><p>In adults, FHL may present with acute onset of full-blown HLH, or as a more insidious illness with recurrent bouts of nonspecific symptoms of HLH which may resolve spontaneously or with steroid treatment alone. HLH in adults is often erroneously attributed to an infectious etiology without a full genetic workup being undertaken.</p><p><b>Common signs and symptoms</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Fever</b> is frequently indolent and protracted but may decline spontaneously. In a few children, it may develop late in the course of the disease.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Splenomegaly</b> and <b>hepatomegaly</b> are usually pronounced and progressive.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Skin rash</b> is uncharacteristic, transient, and often associated with high fever.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Lymph node enlargement</b> develops in fewer than 50% of individuals but may occasionally be significant.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Neurologic abnormalities</b> may be present at initial clinical presentation or in many instances may develop later in the course of the disease. The presentation may include irritability, bulging fontanel in infants, neck stiffness, hypotonia, hypertonia, and convulsions. Cranial nerve VI and/or VII palsy, ataxia, hemiplegia, quadriplegia, blindness, and coma may occur, as well as nonspecific signs of increased intracranial pressure.</div><div class="half_rhythm">On examination of CSF, elevated protein, increased number of mononuclear cells, and occasionally hemophagocytosis are characteristic findings.</div><div class="half_rhythm">MRI may show gross demyelination or failure of normal myelination during the first year of life. MRI may also show multifocal inflammation involving gray and white matter. Bleeding, generalized atrophy, and brain edema may be observed. Hyperdense areas on CT may be falsely interpreted as calcifications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Life expectancy.</b> Median survival in typical FHL, without treatment, is less than two months. Progressive hemophagocytic lymphohistiocytosis (HLH) and invasive infection account for the majority of deaths in untreated children [<a class="bk_pop" href="#hlh.REF.sung.2002.550">Sung et al 2002</a>]. Although children can survive without hematopoietic cell transplantation (HCT) [<a class="bk_pop" href="#hlh.REF.henter.2002.2367">Henter et al 2002</a>], the five-year survival of children treated with chemotherapy alone was only 10.1% in one large series. Allogeneic hematopoietic stem cell transplantation is potentially curative (see <a href="#hlh.Management">Management</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">The course of the disease and life expectancy are not well studied in adults with FHL.</div></li></ul></div><div id="hlh.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Both Feldmann and Molleran Lee documented poor correlation between <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> in FHL2 with different classes of <i>PRF1</i> pathogenic variants [<a class="bk_pop" href="#hlh.REF.feldmann.2002.965">Feldmann et al 2002</a>, <a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</a>].</p><p>In general, age of onset tends to be younger in those with <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> versus <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>PRF1</i> variants [<a class="bk_pop" href="#hlh.REF.clementi.2002.2266">Clementi et al 2002</a>, <a class="bk_pop" href="#hlh.REF.feldmann.2002.965">Feldmann et al 2002</a>, <a class="bk_pop" href="#hlh.REF.zur_stadt.2006.62">zur Stadt et al 2006</a>, <a class="bk_pop" href="#hlh.REF.trizzino.2008.15">Trizzino et al 2008</a>]. In particular, homozygosity for the <i>PRF1</i>
<a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">p.Leu17ArgfsTer34</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, commonly seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of African descent, is associated with an earlier onset (median age 3 months; range 1.5-10 months) compared to other <i>PRF1</i> pathogenic missense variants [<a class="bk_pop" href="#hlh.REF.lee.2006.134">Lee et al 2006</a>]. However, affected individuals within the same family may develop evidence of disease at different ages [<a class="bk_pop" href="#hlh.REF.allen.2001.499">Allen et al 2001</a>].</p><p>In a study of 35 Japanese individuals with FHL, <a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al [2005]</a> concluded that persons with pathogenic variants of <i>PRF1</i> had earlier disease onset than those with pathogenic variants of <i>UNC13D</i> or FHL for whom no genetic basis was established.</p><p>Deficient NK cell activity persisted after chemotherapy in all persons with FHL2, whereas some individuals with FHL3 or the non-FHL2/FHL3 subtype showed partial recovery of NK cell activity during remission.</p><p>Alloantigen-specific CTL-mediated cytotoxicity was deficient in individuals with FHL2 with <i>PRF1</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants and very low in individuals with FHL3, but was only moderately reduced in individuals with FHL2 with <i>PRF1</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants [<a class="bk_pop" href="#hlh.REF.ishii.2005.3442">Ishii et al 2005</a>].</p><p><a class="bk_pop" href="#hlh.REF.ueda.2006.179">Ueda et al [2006]</a> found that the incidence of deficient NK cell activity was higher in those with <i>PRF1</i> pathogenic variants than in those with <i>UNC13D</i> or uncharacterized pathogenic variants. In addition, pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants in <i>PRF1</i> were associated with significantly higher levels of ferritin and soluble Il2Ra than observed in other subtypes of FHL.</p><p><a class="bk_pop" href="#hlh.REF.horne.2008.75">Horne et al [2008]</a> concluded that persons with pathogenic variants of <i>PRF1</i> had earlier onset of symptoms than those with pathogenic variants of <i>STX11</i>, and that the latter had a somewhat milder disease course than those with <i>PRF1</i> variants, <i>UNC13D</i> variants<i>,</i> or uncharacterized pathogenic variants. <a class="bk_pop" href="#hlh.REF.rudd.2006.e14">Rudd et al [2006]</a> reported long remissions without specific treatments in some individuals with <i>STX11</i> pathogenic variants. They also reported a higher than expected incidence of psychomotor retardation and myelodysplastic syndrome or acute myelogenous leukemia in their small group with <i>STX11</i> pathogenic variants. <a class="bk_pop" href="#hlh.REF.marsh.2010b.134">Marsh et al [2010b]</a> noted that pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>STX11</i> were associated with later onset and preserved NK cell function compared to <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants in <i>STX11</i>, which resulted in abrogation of NK cell function.</p><p>In general, the age of onset of disease tends to be later in individuals with pathogenic variants of <i>STXBP2</i> [<a class="bk_pop" href="#hlh.REF.meeths.2010b.2635">Meeths et al 2010b</a>] than it is in individuals with pathogenic variants of <i>PRF1</i> or <i>UNC13D;</i> however, age of onset is variable, even within the same family. Later age at onset in persons with the common <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_stxbp2_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedstxbp2variants" rid-ob="figobhlhTselectedstxbp2variants">c.1247-1G&#x0003e;C</a> variant in <i>STXBP2</i> (both in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> states) in comparison to individuals with various <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants has been reported [zur Stadt et al 2009, <a class="bk_pop" href="#hlh.REF.pagel.2012.6016">Pagel et al 2012</a>]. In contrast, the authors have observed onset of HLH in infancy in more than half of individuals with the c.1247-1G&#x0003e;C variant, as well as considerable discordance in <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and age at onset between sibs with the same <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> [Johnson, unpublished data (2012)]. Gastrointestinal disorders, bleeding diathesis, and hypogammaglobulinemia, with onset often prior to symptoms of HLH, has been reported in a subset of individuals with pathogenic variants of <i>STBXP2</i> [<a class="bk_pop" href="#hlh.REF.meeths.2010b.2635">Meeths et al 2010b</a>].</p><p>Adult onset of disease in individuals with FHL-causing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) has been well described [<a class="bk_pop" href="#hlh.REF.allen.2001.499">Allen et al 2001</a>, <a class="bk_pop" href="#hlh.REF.clementi.2002.2266">Clementi et al 2002</a>, <a class="bk_pop" href="#hlh.REF.ueda.2006.179">Ueda et al 2006</a>]. Missense and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants in <i>PRF1</i>, <i>UNC13D</i> and <i>STXBP2</i> were recently reported in 14% of adults with HLH [<a class="bk_pop" href="#hlh.REF.zhang.2011.5794">Zhang et al 2011</a>]. Similarly, <a class="bk_pop" href="#hlh.REF.sieni.2012b.e44649">Sieni et al [2012b]</a> identified 11 adults with FHL secondary to pathogenic variants in <i>PRF1</i>, <i>UNC13D</i>, <i>STXBP2</i>, and <i>SH2D1A</i>. In both studies, the <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">p.Ala91Var</a> variant in <i>PRF1</i> was the most commonly identified variant. While p.Ala91Var is not by itself pathogenic, it does have an effect on cytotoxic function [<a class="bk_pop" href="#hlh.REF.voskoboinik.2005.4700">Voskoboinik et al 2005</a>] and may function as a genetic modifier of disease in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hlh.Nomenclature"><h3>Nomenclature</h3><p><b>Classification.</b> The widely used modern classification of histiocytic disorders was proposed by the Histiocyte Society in 1987 and refined in 1998.</p><p>The Writing Group of the Histiocyte Society recommended a division of the histiocytic disorders into three classes:</p><ul><li class="half_rhythm"><div>Dendritic cell-related disorders, of which Langerhan's cell histiocytosis (LCH) is by far the most common</div></li><li class="half_rhythm"><div>Macrophage-related disorders (including hemophagocytic lymphohistiocytosis [HLH])</div></li><li class="half_rhythm"><div>Malignant disorders</div></li></ul><p><b>Naming</b></p><ul><li class="half_rhythm"><div>FHL was once called <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> erythrophagocytic lymphohistiocytosis (FEL).</div></li><li class="half_rhythm"><div>FHL occurring in conjunction with identified viral infections was termed VAHS (virus-associated hemophagocytic syndrome); however, it is now recognized that FHL may be triggered by viral infection.</div></li><li class="half_rhythm"><div>The general term hemophagocytic lymphohistiocytosis (HLH) encompasses all forms of the disorder.</div></li></ul></div><div id="hlh.Prevalence"><h3>Prevalence</h3><p>The estimated prevalence of FHL is 1:50,000 births [<a class="bk_pop" href="#hlh.REF.henter.1998.417">Henter et al 1998</a>] with equal gender distribution.</p><p>A common <i>PRF1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">p.Leu17ArgfsTer34</a>, has been observed at a high frequency in individuals with FHL in the African American population [<a class="bk_pop" href="#hlh.REF.lee.2006.134">Lee et al 2006</a>].</p></div></div><div id="hlh.Genetically_Related_Allelic_Disorder"><h2 id="_hlh_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b><i>PRF1</i>.</b> There are reports of other phenotypes associated with mutation of <i>PRF1</i>; the pathologic consequences are not well defined.</p><ul><li class="half_rhythm"><div class="half_rhythm"><a class="bk_pop" href="#hlh.REF.clementi.2005.4424">Clementi et al [2005]</a> reported <i>PRF1</i> sequence variants in a proportion of persons with lymphoma.</div><div class="half_rhythm">Two of four individuals with lymphoma had two <i>PRF1</i> sequence variants, one of which is <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">c.272C&#x0003e;T</a> (<a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">p.Ala91Val</a>), found in about 3% of controls [<a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</a>] and for which understanding of the pathogenic effect is still controversial (see <a href="#hlh.Molecular_Genetics">Molecular Genetics</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><a class="bk_pop" href="#hlh.REF.solomou.2007.5234">Solomou et al [2007]</a> reported an association between mutation of <i>PRF1</i> and acquired aplastic anemia. Three of five reported individuals had the c.272C&#x0003e;T variant described above; a fourth had the <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">c.11G&#x0003e;A</a> (<a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">p.Arg4His</a>) variant, a common <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> in African Americans [<a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</a>]; the fifth had a novel sequence variant. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were reported to have absent or markedly reduced perforin expression and absent perforin staining on microscopy; four of the five had hemophagocytosis in bone marrow.</div></li><li class="half_rhythm"><div class="half_rhythm"><a class="bk_pop" href="#hlh.REF.chia.2009.9809">Chia et al [2009]</a> examined temperature-sensitive <i>PRF1</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in a subset of individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>PRF1</i> pathogenic variants who had not developed hemophagocytic lymphohistiocytosis (HLH) by age ten years. 50% developed at least one hematologic malignancy by adulthood.</div></li><li class="half_rhythm"><div class="half_rhythm"><a class="bk_pop" href="#hlh.REF.orilieri.2008.1078">Orilieri et al [2008]</a> reported an association between the p.Asn252Ser (<a href="/nuccore/NM_001083116.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001083116.1</a>:c.755A&#x0003e;G) variant in <i>PRF1</i> and type 1 diabetes mellitus.</div></li><li class="half_rhythm"><div class="half_rhythm"><a class="bk_pop" href="#hlh.REF.cannella.2007.2566">Cannella et al [2007]</a> described 44 persons with childhood anaplastic large-cell lymphoma, 27.3% of whom had sequence variants in <i>PRF1</i> compared to 10.2% in the general population (p&#x0003c;.01).</div></li></ul><p><b><i>UNC13D.</i></b>
<a class="bk_pop" href="#hlh.REF.zhang.2008.2892">Zhang et al [2008]</a> reported an association between mutation of <i>UNC13D</i> and a specific haplotype with sJIA with macrophage activation syndrome (MAS). However, <a class="bk_pop" href="#hlh.REF.donn.2008.869">Donn et al [2008]</a> failed to confirm an association between systemic onset sJIA/MAS and sequence variants or specific haplotypes in <i>PRF1</i>, <i>GZMB</i>, <i>UNC13D</i>, or <i>RAB27A</i>.</p><p><b><i>STX11</i>.</b> No other phenotypes are known to be associated with mutation of <i>STX11</i>.</p><p><b><i>STXBP2.</i></b> A secondary <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> consisting of colitis, bleeding disorders, and hypogammaglobulinemia has been described in approximately one third of individuals with pathogenic variants in <i>STXBP2</i> [<a class="bk_pop" href="#hlh.REF.meeths.2010b.2635">Meeths et al 2010b</a>]. This phenotype may precede the development of symptoms of HLH; however, data are insufficient to determine if all individuals with pathogenic variants in <i>STXBP2</i> who have this secondary phenotype will develop symptoms of HLH.</p></div><div id="hlh.Differential_Diagnosis"><h2 id="_hlh_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Secondary (acquired or reactive) hemophagocytic lymphohistiocytosis (HLH)</b> is difficult to distinguish from <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> (primary) HLH by clinical or histologic findings alone. Given the rapid advances in genetic diagnosis of FHL, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is recommended even in HLH suspected to be acquired.</p><p>The diagnosis of secondary HLH is usually made in association with infection by viruses, bacteria, fungi, or parasites or in association with lymphoma, autoimmune disease, or metabolic disease [<a class="bk_pop" href="#hlh.REF.imashuku.2000.37">Imashuku et al 2000</a>, <a class="bk_pop" href="#hlh.REF.imashuku.2005.315">Imashuku et al 2005</a>]. Acquired HLH may have decreased, normal, or increased NK cell activity.</p><p>Secondary HLH appears to be self-limited because some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are able to fully recover having received supportive medical treatment (i.e., IV immunoglobulin) alone. However, long-term remission without the use of cytotoxic and immune-suppressive therapies is highly unlikely in adults with HLH and in individuals with CNS involvement [<a class="bk_pop" href="#hlh.REF.imashuku.1999.1869">Imashuku et al 1999</a>].</p><p>Secondary HLH is usually associated with:</p><ul><li class="half_rhythm"><div><b>Infection,</b> particularly involving the herpes virus group, usually in older children and adolescents [<a class="bk_pop" href="#hlh.REF.fisman.2000.601">Fisman 2000</a>]. An example is EBV (Epstein-Barr virus)-associated HLH, which is more common in Asians than in whites or Africans [<a class="bk_pop" href="#hlh.REF.ma.2001.358">Ma et al 2001</a>]. Also in one case, compound heterozygosity for two pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>PRF1</i> was associated with chronic active EBV infection with hemophagocytic lymphohistiocytosis [<a class="bk_pop" href="#hlh.REF.katano.2004.1244">Katano et al 2004</a>].</div></li><li class="half_rhythm"><div><b>"Macrophage activation syndrome" (MAS),</b> the most serious and life-threatening complication of systemic-onset juvenile <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> arthritis (sJIA). MAS was first described by <a class="bk_pop" href="#hlh.REF.hadchouel.1985.561">Hadchouel et al [1985]</a> as a hemorrhagic syndrome associated with mental status changes, hepatosplenomegaly, increased serum concentrations of liver enzymes, and a sharp fall in blood counts. The term MAS was coined by <a class="bk_pop" href="#hlh.REF.st_phan.1993.451">St&#x000e9;phan et al [1993]</a> in reference to the bone marrow histologic findings of numerous, well-differentiated macrophages (or histiocytes) actively phagocytosing hematopoietic elements. Such cells may infiltrate many organs in MAS. MAS responds to therapies similar to those typically effective in HLH. The amount of perforin expressed in NK cells from individuals with severe sJRA is less than in normal controls [<a class="bk_pop" href="#hlh.REF.normand.2000.5406">Normand et al 2000</a>], suggesting a mechanism of immune susceptibility to hemophagocytic lymphohistiocytosis (HLH) similar to FHL2. More recent studies also show that natural killer cell dysfunction is a distinguishing feature of sJIA and MAS [<a class="bk_pop" href="#hlh.REF.villanueva.2005.r30">Villanueva et al 2005</a>].</div></li><li class="half_rhythm"><div><b>Autoimmune diseases,</b> such as rheumatologic disorders, treated with immune suppressive agents [<a class="bk_pop" href="#hlh.REF.janka.1998.435">Janka et al 1998</a>]. Secondary HLH is most commonly associated with sJIA, but has also been observed in systemic lupus erythematosus [<a class="bk_pop" href="#hlh.REF.muiesan.1998.794">Muiesan et al 1998</a>].</div></li><li class="half_rhythm"><div><b>Inborn errors of metabolism</b> including <a href="/books/n/gene/biotin/">biotinidase deficiency</a> [<a class="bk_pop" href="#hlh.REF.kardas.2012.191">Kardas et al 2012</a>], <a href="/books/n/gene/lpi/">lysinuric protein intolerance</a> [<a class="bk_pop" href="#hlh.REF.duval.1999.236">Duval et al 1999</a>], <a href="/books/n/gene/galactosemia/">galactosemia</a> [<a class="bk_pop" href="#hlh.REF.marcoux.2005.160">Marcoux et al 2005</a>], multiple sulfatase deficiency, <a href="/books/n/gene/gaucher/">Gaucher disease</a>, <a href="/books/n/gene/kss/">Pearson syndrome</a>, galactosialidosis, <a href="/books/n/gene/mma/">methylmalonic acidemia</a>, and <a href="/books/n/gene/propionic-a/">propionic acidemia</a> [<a class="bk_pop" href="#hlh.REF.gokce.2012.92">Gokce et al 2012</a>] have all been reported in association with secondary hemophagocytic lymphohistiocytosis in some individuals. It is not known how these metabolic disorders lead to HLH.</div></li></ul><p><b>Inherited immune disorders</b> can be associated with highly lethal hemophagocytic syndromes, sometimes triggered by exposure to EBV or other viruses. These include the following:</p><p><a href="/books/n/gene/x-lpd/"><b>X-linked lymphoproliferative disease</b></a>
<b>(XLP)</b></p><ul><li class="half_rhythm"><div class="half_rhythm">XLP1, caused by SAP deficiency, results from <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> mutation of <i>SH2D1A</i>. The three main phenotypes of this type of XLP are an inappropriate immune response to Epstein-Barr virus (EBV) infection resulting in unusually <b>severe and often fatal infectious mononucleosis, dysgammaglobulinemia,</b> and/or <b>lymphoproliferative disorders</b> typically of B cell origin. Clinical manifestations of XLP1 vary, even among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members. The most common presentation is a near-fatal or fatal EBV infection associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Mortality is greater than 90%. In about one third of males with XLP1, hypogammaglobulinemia of one or more immunoglobulin subclasses is diagnosed prior to EBV infection or in rare survivors of EBV infection. The prognosis for males with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is more favorable if they are managed with regular IV IgG. Lymphomas or other lymphoproliferative disease occur in about one third of males with XLP1, some of whom have hypogammaglobulinemia or have survived an initial EBV infection. The lymphomas seen in XLP1 are typically high-grade B cell lymphomas, non-Hodgkin type, often extranodal, and particularly involving the intestine. Allogeneic HSCT is the only curative therapy for XLP1 and should be undertaken in confirmed cases of XLP1 as early in life as feasible. Average life expectancy without curative bone marrow transplantation has been estimated as less than ten years. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/x-linked-recessive/">X-linked recessive</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">XLP2, caused by XIAP deficiency and resulting from mutation of <i>XIAP</i> (aka <i>BIRC4</i>), is located (as the name implies) on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> [<a class="bk_pop" href="#hlh.REF.rigaud.2006.110">Rigaud et al 2006</a>]. The most common manifestation of XIAP deficiency is the development of HLH, which is often recurrent. Because of this, it has recently been suggested that XIAP deficiency may be best classified as a cause of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> HLH [<a class="bk_pop" href="#hlh.REF.marsh.2010a.1079">Marsh et al 2010a</a>].</div><div class="half_rhythm">Hypogammaglobulinemia and colitis have also been described in individuals with XIAP deficiency. In contrast to XLP1, no cases of lymphoma have been observed in individuals with XIAP deficiency [<a class="bk_pop" href="#hlh.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</a>]. Patient management includes treatment of HLH when it occurs, immunoglobulin replacement if needed, and consideration of allogeneic bone marrow transplant.</div></li></ul><p><a href="/books/n/gene/chediak-higashi/"><b>Chediak-Higashi syndrome</b></a> is a complex syndrome characterized by partial albinism, abnormal platelet function, and severe immunodeficiency. This disorder is caused by mutation of <i>CHS1</i>, which encodes a protein involved in intracellular vesicle formation, resulting in a failure to fuse lysosomes properly with phagosomes. Chediak-Higashi syndrome can be differentiated from FHL based on the presence of huge secretory lysosomes in the neutrophils and lymphocytes and giant melanosomes on skin biopsy. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><b>Griscelli syndrome type 2 (GS2)</b> is a disorder of cytotoxic T lymphocytes caused by mutation of a small GTPase, <i>RAB27A</i>, which controls the movement of vesicles within cells [<a class="bk_pop" href="#hlh.REF.m_nasch_.2000.173">M&#x000e9;nasch&#x000e9; et al 2000</a>]. GS2 is usually associated with neurologic abnormalities in addition to partial albinism with fair skin and silvery-grey hair and has an extremely high incidence of HLH. A recent Swedish study identified <i>RAB27A</i> pathogenic variants in 5% of individuals with primary HLH and without a known diagnosis of GS2 [<a class="bk_pop" href="#hlh.REF.meeths.2010a.563">Meeths et al 2010a</a>]. GS2 and FHL3 may share a common pathway: <a class="bk_pop" href="#hlh.REF.neeft.2005.731">Neeft et al [2005]</a> showed that the protein encoded by <i>UNC13D</i> is a direct partner of the protein RAB27A, and that the RAB27A/UNC13D complex is essential in the regulation of secretory granule fusion with the plasma membrane in hematopoietic cells. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p></div><div id="hlh.Management"><h2 id="_hlh_Management_">Management</h2><div id="hlh.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with hemophagocytic lymphohistiocytosis (HLH), as well as to determine the appropriate therapy, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Physical examination to evaluate for rashes, lymphadenopathy, hepatosplenomegaly, and neurologic dysfunction</div></li><li class="half_rhythm"><div>Evaluation of blood and bone marrow compartments (CBC and BM biopsy)</div></li><li class="half_rhythm"><div>Determination of the extent of liver involvement by measuring serum concentration of transaminases, bilirubin, triglycerides, sodium, and lactate dehydrogenase</div></li><li class="half_rhythm"><div>Identification of potential infectious co-factors, especially viral infection or reactivation, which would require specific treatment</div></li><li class="half_rhythm"><div>Establishing the presence or extent of CNS involvement by evaluating the CSF and performing neuroimaging and neuropsychological assessment</div></li><li class="half_rhythm"><div>Testing of NK cell activity, intracellular perforin and granzyme B expression, and CD107a mobilization if these tests are available</div></li><li class="half_rhythm"><div>Evaluation of inflammatory factors such as serum concentrations of ferritin, sIL2R&#x003b1;, and other cytokines</div></li><li class="half_rhythm"><div>Evaluation and monitoring of PT, PTT, and fibrinogen</div></li><li class="half_rhythm"><div>Clinical genetics consultation</div></li><li class="half_rhythm"><div>Molecular genetic testing, if not performed previously, which may help to determine if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is a candidate for bone marrow transplantation:</div><ul><li class="half_rhythm"><div>Genetic testing for <i>PRF1</i>, <i>UNC13D</i>, <i>STX11</i>, and <i>STXBP2</i> pathogenic variants</div></li><li class="half_rhythm"><div>Consideration of testing for <i>RAB27A</i> pathogenic variants in any individual with HLH, even with no obvious evidence of depigmentation</div></li><li class="half_rhythm"><div>Consideration of testing for <i>XIAP</i> (formerly <i>BIRC4</i>) and <i>SH2D1A</i> pathogenic variants in any male with HLH</div></li><li class="half_rhythm"><div>Collection of materials for future characterization of underlying genetic defects, most significantly in individuals with terminal disease</div></li></ul></li></ul></div><div id="hlh.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>For a detailed explanation of treatment for HLH, see <a class="bk_pop" href="#hlh.REF.jordan.2011.4041">Jordan et al [2011]</a> (<a href="/pmc/articles/PMC3204727/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p><b>HLH-1994.</b> To improve survival, in 1994 the Histiocyte Society initiated a prospective international collaborative therapeutic study. It combined chemotherapy and immunotherapy (etoposide, corticosteroids, cyclosporine A, and intrathecal methotrexate for individuals with CNS diseases), followed by HSCT in persistent, recurring, and/or <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> disease. Although HLH-94 was primarily designed for the treatment of FHL, it was also open to all individuals with non-familial HLH.</p><p><b>HLH-2004.</b> The HLH-2004 protocol was opened on January 1, 2004, and was designed for individuals with FHL and non-<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> HLH. This protocol was based on the HLH-94 protocol with minor therapeutic modifications such as initiation of cyclosporine from onset of induction therapy.</p><p>The two protocols developed by the Histiocyte Society are available from the Histiocyte Society <a href="https://www.histiocytesociety.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">website</a>.</p><p>Given the poor prognosis of individuals with HLH without prompt and effective treatment, it is recommended that treatment be initiated when clinical suspicion is high, even if all recommended studies are incomplete. In general, treatment involves the following:</p><ul><li class="half_rhythm"><div>Chemotherapy and immunotherapy to achieve a clinically stable resolution prior to hematopoietic cell transplantation (HCT)</div></li><li class="half_rhythm"><div>Antibiotics or antiviral agents to treat or prevent infections that may have triggered the exaggerated inflammatory response</div></li><li class="half_rhythm"><div>Allogeneic HCT, the only curative therapy, which should be undertaken in children with confirmed FHL as early in life as feasible:</div><ul><li class="half_rhythm"><div>Presymptomatically if status is confirmed by family history of clinical HLH, or</div></li><li class="half_rhythm"><div>After achievement of clinical remission in <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family)</div></li></ul></li><li class="half_rhythm"><div>Use of HCT has improved survival significantly [<a class="bk_pop" href="#hlh.REF.henter.2002.2367">Henter et al 2002</a>]. Initially, three-year-survival in children who received HLH-94 therapy was approximately 64% [<a class="bk_pop" href="#hlh.REF.horne.2005a.622">Horne et al 2005a</a>]. More recently, reduced intensity regimens prior to HCT have diminished the early transplant mortality and increased three-year-survival rates to 92% [<a class="bk_pop" href="#hlh.REF.marsh.2010c.5824">Marsh et al 2010c</a>]. Long-term follow up reveals that after HCT most children treated early in the disease course return to normal or near-normal quality of life. Brain atrophy secondary to steroid therapy often identified on neuroimaging studies during the acute phase of HLH gradually resolves after HCT [<a class="bk_pop" href="#hlh.REF.shuper.1998.126">Shuper et al 1998</a>]. However, children who experienced serious CNS involvement may have irreversible neurologic problems and learning disabilities despite adequate disease control following HCT.</div></li></ul></div><div id="hlh.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Allogeneic HCT is the only curative therapy and should be undertaken in children with confirmed <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> HLH as early in life as possible.</p></div><div id="hlh.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Prompt treatment of HLH with infection prophylaxis is indicated in immunocompromised individuals.</p></div><div id="hlh.Surveillance"><h3>Surveillance</h3><p>The following are recommended annually after HCT:</p><ul><li class="half_rhythm"><div>Neuropsychological evaluation</div></li><li class="half_rhythm"><div>Regular follow-up by transplant specialists to monitor for late complications relating to growth and hormone function</div></li></ul></div><div id="hlh.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Live vaccinations</div></li><li class="half_rhythm"><div>Exposure to infections</div></li></ul></div><div id="hlh.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Molecular genetic testing of at-risk sibs for the family-specific pathogenic variants is appropriate to identify those who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> before symptoms occur for the purpose of early medical management and consideration of presymptomatic bone marrow transplantation.</p><p>See <a href="#hlh.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hlh.Pregnancy_Management"><h3>Pregnancy Management</h3><p>To date, pregnancy in a woman with primary FHL has not been described. Secondary hemophagocytic lymphohistiocytosis is a rare complication of pregnancy and is beyond the scope of this review. Primary hemophagocytic lymphohistiocytosis in the fetus is a (reportedly) rare but recognized entity which is typically characterized by nonimmune fetal hydrops [<a class="bk_pop" href="#hlh.REF.malloy.2004.458">Malloy et al 2004</a>, <a class="bk_pop" href="#hlh.REF.nitta.2007.98">Nitta et al 2007</a>, <a class="bk_pop" href="#hlh.REF.woods.2009.265">Woods et al 2009</a>], preterm delivery [<a class="bk_pop" href="#hlh.REF.woods.2009.265">Woods et al 2009</a>], and/or fetal demise. In utero chemotherapy followed by post-natal HCT has been described [<a class="bk_pop" href="#hlh.REF.shah.2009.139">Shah et al 2009</a>].</p></div><div id="hlh.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="hlh.Other"><h3>Other</h3><p>The treatment of FHL is also the most effective treatment for secondary HLH and the hemophagocytic syndrome associated with other inherited immunodeficiencies.</p></div></div><div id="hlh.Genetic_Counseling"><h2 id="_hlh_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hlh.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Familial hemophagocytic lymphohistiocytosis (FHL) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="hlh.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes and therefore carry one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with FHL are obligate heterozygotes (carriers).</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="hlh.Carrier_Detection"><h3>Carrier Detection</h3><p>Carrier testing is possible if the pathogenic variants in the family are known.</p></div><div id="hlh.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hlh.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Testing of at-risk asymptomatic sibs</b> for FHL is possible using the techniques described in <a href="#hlh.Molecular_Genetic_Testing">Molecular Genetic Testing</a>. Such testing is not useful in accurately predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. However, expectant management is warranted for individuals with the same <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> as the symptomatic <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and HCT prior to onset of symptoms may improve outcome.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hlh.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="hlh.Resources"><h2 id="_hlh_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Histiocytosis Association</b></div><div> NJ </div><div><b>Phone:</b> 856-589-6606</div><div><b>Fax:</b> 856-589-6614</div><div><b>Email:</b> info@histio.org</div><div><a href="https://www.histio.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.histio.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li></ul></div><div id="hlh.Molecular_Genetics"><h2 id="_hlh_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hlh.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hemophagocytic Lymphohistiocytosis, Familial: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hlh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Locus Name</th><th id="hd_b_hlh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hlh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hlh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hlh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hlh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hlh.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hlh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">FHL1</td><td headers="hd_b_hlh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Unknown</td><td headers="hd_b_hlh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_hlh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Unknown</td><td headers="hd_b_hlh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_hlh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_hlh.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_b_hlh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">FHL2</td><td headers="hd_b_hlh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5551" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PRF1</i></a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5551" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P14222" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Perforin-1</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=PRF1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (PRF1)</a><br /><a href="http://structure.bmc.lu.se/idbase/PRF1base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PRF1base: Mutation registry for Familiar haemophagocytic lymphohistiocytosis, type II (FHL2)</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PRF1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PRF1</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PRF1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PRF1</a></td></tr><tr><td headers="hd_b_hlh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">FHL3</td><td headers="hd_b_hlh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/201294" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>UNC13D</i></a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=201294" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q25<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q70J99" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Protein unc-13 homolog D</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=UNC13D" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (UNC13D)</a><br /><a href="http://structure.bmc.lu.se/idbase/UNC13Dbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UNC13Dbase: Mutation registry for Familial hemophagocytic lymphohistiocytosis 3</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=UNC13D" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UNC13D</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=UNC13D[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UNC13D</a></td></tr><tr><td headers="hd_b_hlh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">FHL4</td><td headers="hd_b_hlh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8676" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>STX11</i></a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8676" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6q24<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O75558" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Syntaxin-11</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=STX11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (STX11)</a><br /><a href="http://structure.bmc.lu.se/idbase/STX11base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">STX11base: Mutation registry for Familial haemophagocytic lymphohistiocytosis 4 (FHL4)</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=STX11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">STX11</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=STX11[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">STX11</a></td></tr><tr><td headers="hd_b_hlh.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">FHL5</td><td headers="hd_b_hlh.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6813" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>STXBP2</i></a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6813" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q15833" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Syntaxin-binding protein 2</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=STXBP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (STXBP2)</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=STXBP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">STXBP2</a></td><td headers="hd_b_hlh.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=STXBP2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">STXBP2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hlh.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hlh.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hemophagocytic Lymphohistiocytosis, Familial (<a href="/omim/170280,267700,601717,603552,603553,605014,608897,608898,613101" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/170280" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">170280</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PERFORIN 1; PRF1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/267700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">267700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601717" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601717</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SYNTAXIN-BINDING PROTEIN 2; STXBP2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603552" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603552</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603553" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603553</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605014" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605014</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SYNTAXIN 11; STX11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608897" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608897</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UNC13 HOMOLOG D; UNC13D</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608898" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608898</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613101" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613101</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 5; FHL5</td></tr></tbody></table></div></div><p><b><i>PRF1</i></b></p><p><b>Gene structure.</b>
<i>PRF1</i> has three exons; exons 2 and 3 encode a 555-amino acid polypeptide. Genomic DNA of <i>PRF1</i> spans about 5 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1444/#hlh.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> To date, several benign variants have been observed (see <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedprf1variants" rid-ob="figobhlhTselectedprf1variants">Table 3</a>). These have been evaluated by biochemical and functional testing in vitro and are highly unlikely to have pathogenic effects on perforin expression.</p><p><b>Pathogenic variants.</b> To date, more than 115 pathogenic variants have been identified. They have been found throughout the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>. Pathogenic variants in <i>PRF1</i> include <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, small deletions, and small insertions [<a class="bk_pop" href="#hlh.REF.voskoboinik.2005.4700">Voskoboinik et al 2005</a>]. To date, no gross deletions, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, or complex rearrangements have been reported.</p><p>The variant c.272C&#x0003e;T has been reported as a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#hlh.REF.clementi.2001.643">Clementi et al 2001</a>]. This sequence variant is identified in about 3% of the North American general population [<a class="bk_pop" href="#hlh.REF.molleran_lee.2004.137">Molleran Lee et al 2004</a>] and in a much higher proportion of patients with FHL [<a class="bk_pop" href="#hlh.REF.busiello.2006.123">Busiello et al 2006</a>, <a class="bk_pop" href="#hlh.REF.zhang.2007.231">Zhang et al 2007</a>]. Earlier studies have shown that the sequence change c.272C&#x0003e;T results in reduced levels of perforin expression [<a class="bk_pop" href="#hlh.REF.voskoboinik.2005.4700">Voskoboinik et al 2005</a>] and that p.Ala91Val perforin has reduced cytotoxicity in CTL and NK cells [<a class="bk_pop" href="#hlh.REF.trambas.2005.932">Trambas et al 2005</a>]. In addition, Voskoboinik showed that the c.272C&#x0003e;T (p.Ala91Val) substitution in perforin not only causes reduced steady state levels of expression in effector cells, but also results in a reduced intrinsic capacity for lysis and even had some <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect on the wild type perforin [<a class="bk_pop" href="#hlh.REF.voskoboinik.2007.1184">Voskoboinik et al 2007</a>]. Even though c.272C&#x0003e;T by itself is not disease causing, these cumulative data suggest that the sequence variant may be an important genetic susceptibility factor and may play a role in the disease process.</p><div id="hlh.T.selected_prf1_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>PRF1</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.T.selected_prf1_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.T.selected_prf1_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlh.T.selected_prf1_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change&#x000a0;<sup>1</sup><br />(Alias&#x000a0;<sup>2</sup>)</th><th id="hd_h_hlh.T.selected_prf1_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.11G&#x0003e;A</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg4His</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_4" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/133908620" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001083116<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="/protein/133908621" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001076585<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.368G&#x0003e;A</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg123His</td></tr><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.726C&#x0003e;T</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(=)<br />(Cys242Cys)</td></tr><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.822C&#x0003e;T</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(=)<br />(Ala274Ala)</td></tr><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.900C&#x0003e;T</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(=)<br />(His300His)</td></tr><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.272C&#x0003e;T&#x000a0;<sup>3</sup></td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala91Val&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.50delT</td><td headers="hd_h_hlh.T.selected_prf1_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu17ArgfsTer34</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="hlh.TF.3.1"><p class="no_margin">p.(=) designates that protein has not been analyzed, but no change is expected</p></div></dd><dt>2. </dt><dd><div id="hlh.TF.3.2"><p class="no_margin">Variant designation that does not conform to current nomenclature</p></div></dd><dt>3. </dt><dd><div id="hlh.TF.3.3"><p class="no_margin">Not disease-causing, but proposed as a genetic susceptibility factor or disease modifier (see <a href="#hlh.Molecular_Genetics"><i>PRF1</i></a><b><i>,</i> Pathogenic variants</b>)</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PRF1</i> encodes the cytolytic effector perforin, which is expressed by cytolytic T lymphocytes and NK cells [<a class="bk_pop" href="#hlh.REF.stepp.1999.1957">Stepp et al 1999</a>]. Perforin expression is higher in resting than in activated cells. Perforin induces apoptotic cell death in response to granzymes (serine esterases that represent most of the granule content of T cytotoxic cells) independent from the FAS-mediated apoptotic machinery.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PRF1</i> pathogenic variants affect cellular cytotoxicity, resulting in impaired antiviral defense and dysregulation of apoptotic mechanisms involved in the regulation of immune responses to inappropriate proliferation of cells, such as T cells and macrophages. Although the mechanisms of regulating perforin expression are incompletely understood, it is known that <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> of a promoter-specific region does affect the level of perforin expression.</p><p><b><i>UNC13D</i> (<i>MUNC13-4</i>)</b></p><p><b>Gene structure.</b>
<i>UNC13D</i> consists of 32 exons ranging from 36 to 235 bp in size. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1444/#hlh.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> A dozen benign variants, which are highly unlikely to have pathogenic effects on UNC13D protein expression, have been observed.</p><p><b>Pathogenic variants.</b> To date, more than 100 pathogenic variants have been identified throughout the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> and the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> boundaries of <i>UNC13D</i>. Pathogenic variants that have been identified include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants and small deletions and/or insertions. One deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variant (c.118-308C&#x0003e;T) and one large <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> inversion have been detected [<a class="bk_pop" href="#hlh.REF.meeths.2011.5783">Meeths et al 2011</a>]. A large 253-kb inversion straddles the <i>UNC13D</i> 3&#x02019; end and adjacent sequences; the breakpoints have been mapped and it is detectable by <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> (<a class="figpopup" href="/books/NBK1444/table/hlh.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fighlhTmoleculargenetictestingusedin" rid-ob="figobhlhTmoleculargenetictestingusedin">Table 2</a>). The deep intronic variant lies in a region typically not sequenced; detection will require specific primers.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein encoded by <i>UNC13D</i> has 1090 amino acids and is a member of the Munc13 protein family, which is an essential effector of the cytolytic secretory pathway. UNC13D differs from the other Munc13 proteins, as it is not expressed in the brain but rather is highly expressed in hematopoietic tissues including T- and B-lymphocytes and monocytes and in non-hematopoietic tissues, such as the lung and the placenta.</p><p>UNC13D is involved in vesicle-plasma membrane fusion during exocytosis of perforin- and granzyme-containing granules by cytotoxic T cells and NK cells [<a class="bk_pop" href="#hlh.REF.feldmann.2002.965">Feldmann et al 2002</a>, <a class="bk_pop" href="#hlh.REF.m_nager.2007.257">M&#x000e9;nager et al 2007</a>], which follows granule docking and precedes plasma granule membrane fusion [<a class="bk_pop" href="#hlh.REF.m_nasch_.2005.165">M&#x000e9;nasch&#x000e9; et al 2005</a>].</p><p>UNC13D is a direct partner of RAB27A. The two proteins are highly expressed in cytotoxic T-cells (CTLs) and mast cells, where they colocalize on secretory lysosomes. Together, they assist priming the vesicles for exocytosis [<a class="bk_pop" href="#hlh.REF.m_nager.2007.473">M&#x000e9;nager &#x00026; de Saint Basile 2007</a>]. The region comprising the Munc13 homology domains is essential for the localization of UNC13D to secretory lysosomes [<a class="bk_pop" href="#hlh.REF.neeft.2005.731">Neeft et al 2005</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>UNC13D</i> prevent interaction with RAB27A and abolish cytolytic secretion [<a class="bk_pop" href="#hlh.REF.neeft.2005.731">Neeft et al 2005</a>]. Individuals with <i>UNC13D</i> pathogenic variants have impaired lymphocyte cytotoxic function with normal or increased perforin expression. Interestingly, the c.118-308C&#x0003e;T <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> impairs transcription in lymphocytes, but not some other cell types [<a class="bk_pop" href="#hlh.REF.meeths.2011.5783">Meeths et al 2011</a>].</p><div id="hlh.T.selected_unc13d_pathogenic_variant" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>UNC13D</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.T.selected_unc13d_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.T.selected_unc13d_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.118-308C&#x0003e;T</td><td headers="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_199242.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_199242<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_954712.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_954712<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(253-kb inversion)</td><td headers="hd_h_hlh.T.selected_unc13d_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd></dl></div></div></div><p><b><i>STX11</i></b></p><p><b>Gene structure.</b>
<i>STX11</i> consists of two exons. Exon 2 encodes 287 amino acid residues. Genomic DNA of <i>STX11</i> spans about 37 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1444/#hlh.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> To date, three benign variants have been identified [Zhang, unpublished (2010)]; they are highly unlikely to have pathogenic effects on <i>STX11</i> protein expression. See <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_stx11_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedstx11variants" rid-ob="figobhlhTselectedstx11variants">Table 5</a>.</p><p><b>Pathogenic variants.</b> A total of nine distinct pathogenic variants have been reported, including in three families in highly <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> Turkish/Kurdish FHL4 kindreds. <i>STX11</i> pathogenic variants have been found in individuals with FHL from other ethnic backgrounds, albeit at a low frequency [<a class="bk_pop" href="#hlh.REF.marsh.2010b.134">Marsh et al 2010b</a>]. See <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_stx11_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedstx11variants" rid-ob="figobhlhTselectedstx11variants">Table 5</a>. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>STX11</i> variants have been reported in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals to date. A whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <i>STX11</i> has been reported [<a class="bk_pop" href="#hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</a>].</p><div id="hlh.T.selected_stx11_variants" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Selected <i>STX11</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.T.selected_stx11_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.T.selected_stx11_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlh.T.selected_stx11_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant<br />Classification</th><th id="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hlh.T.selected_stx11_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.146G&#x0003e;A</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg49Gln</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_4" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/187423911" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003764<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/33667038" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003755<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.546G&#x0003e;A</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu182Gln</td></tr><tr><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.651G&#x0003e;T</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu217Leu</td></tr><tr><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.[369_370delAG; 374_379delCGC]<br />(5-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>)</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val124GlyfsTer60</td></tr><tr><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.802C&#x0003e;T</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln268Ter</td></tr><tr><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">g.25560_44750del<br />(19.2-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>)</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_hlh.T.selected_stx11_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/12666200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AL135917</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene product of <i>STX11</i> is known for its function in vesicle transport. It is a member of soluble N-ethylmaleimide sensitive factor attachment protein receptors present on target membranes (t-SNAREs) [<a class="bk_pop" href="#hlh.REF.zur_stadt.2005.827">zur Stadt et al 2005</a>]. STX11 is expressed in peripheral mononuclear cells, as well as in unstimulated NK cells and CD8+ T cells [<a class="bk_pop" href="#hlh.REF.bryceson.2007.1906">Bryceson et al 2007</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The absence of the STX11 protein has been observed in monocytes and lymphocytes in persons with FHL4. The abrogation of degranulation and cytotoxicity by resting PBLs observed in this disorder are believed to be caused by the defects in <i>STX11</i> [<a class="bk_pop" href="#hlh.REF.arneson.2007.3397">Arneson et al 2007</a>].</p><p><b><i>STXBP2</i></b></p><p><b>Gene structure.</b>
<i>STXBP2</i> is located on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 19p13.3-p13.2 and its <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA spans about 11 kb. <i>STXBP2</i> comprises 19 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1444/#hlh.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> To date, more than two dozen benign variants have been identified [Zhang, unpublished (2012)]; they are highly unlikely to have pathogenic effects on STXBP2 protein expression. For example, the <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> <a class="figpopup" href="/books/NBK1444/table/hlh.T.selected_stxbp2_variants/?report=objectonly" target="object" rid-figpopup="fighlhTselectedstxbp2variants" rid-ob="figobhlhTselectedstxbp2variants">p.Ala433Val</a> did not affect binding between syntaxin-11 and UNC13B [<a class="bk_pop" href="#hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</a>].</p><p><b>Pathogenic variants.</b> To date, 27 pathogenic variants have been identified throughout the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> and the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> boundaries of <i>STXBP2</i>. Identified variants include pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants as well as small deletions and/or insertions. Gross deletions, insertions, and other complex variants have not been observed to date [Zhang, unpublished (2012)].</p><div id="hlh.T.selected_stxbp2_variants" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Selected <i>STXBP2</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1444/table/hlh.T.selected_stxbp2_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlh.T.selected_stxbp2_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1298C&#x0003e;T</td><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala433Val</td><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_006949.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_006949<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_008880.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_008880<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1247-1G&#x0003e;C</td><td headers="hd_h_hlh.T.selected_stxbp2_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>STXBP</i>2 encodes syntaxin-11, a polypeptide of 593 amino acids and a member of the STXBP/Munc-18/Sec1 family. Syntaxin-11, formerly known as UNC18B, is expressed predominantly as a 2.4-kb message in placenta, lung, liver, kidney, and pancreas, as well as in peripheral blood lymphocytes [<a class="bk_pop" href="#hlh.REF.ziegler.1996.19">Ziegler et al 1996</a>]. It interacts with soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) syntaxins, and regulates intracellular vesicle trafficking [<a class="bk_pop" href="#hlh.REF.c_te.2009.3765">C&#x000f4;te et al 2009</a>]. Like other Sec/Munc18 family members, <i>STXBP2</i> has three domains and forms an arch-shaped structure. The central cavity, formed by domains 1 and 3a, provide the binding surface for syntaxin-11. In addition, <i>STXBP2</i> and <i>STX11</i> share binding sites and are colocalized in CD8+ T and NK cells. Stimulation with IL2 can further enhance colocalization in CD8+ and NK cells [<a class="bk_pop" href="#hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<a class="bk_pop" href="#hlh.REF.zur_stadt.2009.482">zur Stadt et al [2009]</a> showed that <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>STXBP2</i> can lead to a complete loss of the ability to bind to syntaxin-11. Cultured NK cells from patients with pathogenic variants in <i>STXBP2</i> exhibit impaired cytotoxic granule exocytosis with decreased or absent CD107 expression. <i>Ex vivo</i> cytotoxicity in NK and cytotoxic T-cell were both decreased [<a class="bk_pop" href="#hlh.REF.meeths.2010b.2635">Meeths et al 2010b</a>]. However, degranulation and cytotoxicity could be at least partially corrected by in vitro stimulation with IL2 [<a class="bk_pop" href="#hlh.REF.zur_stadt.2009.482">zur Stadt et al 2009</a>]. Defects in <i>STXBP2</i> can reduce or completely abolish syntaxin-11 expression. In contrast, STXBP2 expression does not require syntaxin-11 [<a class="bk_pop" href="#hlh.REF.c_te.2009.3765">C&#x000f4;te et al 2009</a>].</p></div><div id="hlh.References"><h2 id="_hlh_References_">References</h2><div id="hlh.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.allen.2001.499">Allen M, De Fusco C, Legrand F, Clementi R, Conter V, Danesino C, Janka G, Aric&#x000f2; M. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? <span><span class="ref-journal">Haematologica. </span>2001;<span class="ref-vol">86</span>:499–503.</span> [<a href="/pubmed/11410413" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11410413</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.aric_.1996.197">Aric&#x000f2; M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, Martinetti M, Rusca MP. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. <span><span class="ref-journal">Leukemia. </span>1996;<span class="ref-vol">10</span>:197–203.</span> [<a href="/pubmed/8637226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8637226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.arneson.2007.3397">Arneson LN, Brickshawana A, Segovis CM, Schoon RA, Dick CJ, Leibson PJ. Cutting edge: syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. <span><span class="ref-journal">J Immunol. </span>2007;<span class="ref-vol">179</span>:3397–401.</span> [<a href="/pubmed/17785771" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17785771</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.bryceson.2007.1906">Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, Bechensteen AG, Boelens JJ, Celkan T, Farah RA, Hultenby K, Winiarski J, Roche PA, Nordenskj&#x000f6;ld M, Henter JI, Long EO, Ljunggren HG. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:1906–15.</span> [<a href="/pmc/articles/PMC1976360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1976360</span></a>] [<a href="/pubmed/17525286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17525286</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.busiello.2006.123">Busiello R, Fimiani G, Miano MG, Aric&#x000f2; M, Santoro A, Ursini MV, Pignata C. A91V perforin variation in healthy subjects and FHLH patients. <span><span class="ref-journal">Int J Immunogenet. </span>2006;<span class="ref-vol">33</span>:123–5.</span> [<a href="/pubmed/16611257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16611257</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.cannella.2007.2566">Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L, Mangili G, Rosolen A, Aric&#x000f2; M. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. <span><span class="ref-journal">Cancer. </span>2007;<span class="ref-vol">109</span>:2566–71.</span> [<a href="/pubmed/17477373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17477373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.chia.2009.9809">Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2009;<span class="ref-vol">106</span>:9809–14.</span> [<a href="/pmc/articles/PMC2701033/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2701033</span></a>] [<a href="/pubmed/19487666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19487666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.clementi.2002.2266">Clementi R, Emmi L, Maccario R, Liotta F, Moretta L, Danesino C, Aric&#x000f3; M. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. <span><span class="ref-journal">Blood. </span>2002;<span class="ref-vol">100</span>:2266–7.</span> [<a href="/pubmed/12229880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12229880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.clementi.2005.4424">Clementi R, Locatelli F, Dupr&#x000e9; L, Garaventa A, Emmi L, Bregni M, Cefalo G, Moretta A, Danesino C, Comis M, Pession A, Ramenghi U, Maccario R, Aric&#x000f2; M, Roncarolo MG. A proportion of patients with lymphoma may harbor mutations of the perforin gene. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:4424–8.</span> [<a href="/pubmed/15728124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15728124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.clementi.2001.643">Clementi R, zur Stadt U, Savoldi G, Varoitto S, Conter V, De Fusco C, Notarangelo LD, Schneider M, Klersy C, Janka G, Danesino C, Aric&#x000f2; M. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:643–6.</span> [<a href="/pmc/articles/PMC1734943/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734943</span></a>] [<a href="/pubmed/11565555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11565555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.c_te.2009.3765">C&#x000f4;te M, M&#x000e9;nager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, Al-Manjomi F, Al-Harbi M, Alangari A, Le Deist F, Gennery AR, Prince N, Cariou A, Nitschke P, Blank U, El-Ghazali G, M&#x000e9;nasch&#x000e9; G, Latour S, Fischer A, de Saint Basile G. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:3765–73.</span> [<a href="/pmc/articles/PMC2786810/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2786810</span></a>] [<a href="/pubmed/19884660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19884660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.donn.2008.869">Donn R, Ellison S, Lamb R, Day T, Baildam E, Ramanan AV. Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. <span><span class="ref-journal">Arthritis Rheum. </span>2008;<span class="ref-vol">58</span>:869–74.</span> [<a href="/pmc/articles/PMC2675009/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2675009</span></a>] [<a href="/pubmed/18311812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18311812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.duval.1999.236">Duval M, Fenneteau O, Doireau V, Faye A, Emilie D, Yotnda P, Drapier JC, Schlegel N, Sterkers G, de Baulny HO, Vilmer E. Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">134</span>:236–9.</span> [<a href="/pubmed/9931537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9931537</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.feldmann.2002.965">Feldmann J, Le Deist F, Ouach&#x000e9;e-Chardin M, Certain S, Alexander S, Quartier P, Haddad E, Wulffraat N, Casanova JL, Blanche S, Fischer A, de Saint Basile G. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:965–72.</span> [<a href="/pubmed/12060139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12060139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.filipovich.2011.512">Filipovich AH. The expanding spectrum of hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Curr Opin Allergy Clin Immunol. </span>2011;<span class="ref-vol">11</span>:512–6.</span> [<a href="/pubmed/21971331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21971331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.fisman.2000.601">Fisman DN. Hemophagocytic syndromes and infection. <span><span class="ref-journal">Emerg Infect Dis. </span>2000;<span class="ref-vol">6</span>:601–8.</span> [<a href="/pmc/articles/PMC2640913/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2640913</span></a>] [<a href="/pubmed/11076718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11076718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.gokce.2012.92">Gokce M, Unal O, Hismi B, Gumruk F, Coskun T, Balta G, Unal S, Cetin M, Kalkanoglu-Sivri HS, Dursun A, Tokatl&#x00131; A. Secondary hemophagocytosis in 3 patients with organic acidemia involving propionate metabolism. <span><span class="ref-journal">Pediatr Hematol Oncol. </span>2012;<span class="ref-vol">29</span>:92–8.</span> [<a href="/pubmed/21970506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21970506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.g_ransdotter_ericson.2001.590">G&#x000f6;ransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, S&#x000f6;derh&#x000e4;ll C, Samuelsson A, Janka G, Schneider M, G&#x000fc;rgey A, Yalman N, R&#x000e9;v&#x000e9;sz T, Egeler R, Jahnukainen K, Storm-Mathiesen I, Haraldsson A, Poole J, de Saint Basile G, Nordenskj&#x000f6;ld M, Henter J. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:590–7.</span> [<a href="/pmc/articles/PMC1274472/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274472</span></a>] [<a href="/pubmed/11179007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11179007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.hadchouel.1985.561">Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. <span><span class="ref-journal">J Pediatr. </span>1985;<span class="ref-vol">106</span>:561–6.</span> [<a href="/pubmed/3981309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3981309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.henter.1998.417">Henter JI, Aric&#x000f2; M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>1998;<span class="ref-vol">12</span>:417–33.</span> [<a href="/pubmed/9561910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9561910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.henter.2007.124">Henter JI, Horne A, Aric&#x000f3; M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2007;<span class="ref-vol">48</span>:124–31.</span> [<a href="/pubmed/16937360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16937360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.henter.2002.2367">Henter JI, Samuelsson-Horne A, Aric&#x000f2; M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G. Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. <span><span class="ref-journal">Blood. </span>2002;<span class="ref-vol">100</span>:2367–73.</span> [<a href="/pubmed/12239144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12239144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.horne.2005a.622">Horne A, Janka G, Maarten Egeler R, Gadner H, Imashuku S, Ladisch S, Locatelli F, Montgomery SM, Webb D, Winiarski J, Filipovich AH, Henter JI. Histiocyte Society. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Br J Haematol. </span>2005a;<span class="ref-vol">129</span>:622–30.</span> [<a href="/pubmed/15916685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15916685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.horne.2008.75">Horne A, Ramme KG, Rudd E, Zheng C, Wali Y, al-Lamki Z, G&#x000fc;rgey A, Yalman N, Nordenskj&#x000f6;ld M, Henter JI. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">143</span>:75–83.</span> [<a href="/pubmed/18710388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18710388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.horne.2005b.658">Horne A, Zheng C, Lorenz I, L&#x000f6;fstedt M, Montgomery SM, Janka G, Henter JI, Marion Schneider E. Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. <span><span class="ref-journal">Br J Haematol. </span>2005b;<span class="ref-vol">129</span>:658–66.</span> [<a href="/pubmed/15916689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15916689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.imashuku.1999.1869">Imashuku S, Hibi S, Ohara T, Iwai A, Sako M, Kato M, Arakawa H, Sotomatsu M, Kataoka S, Asami K, Hasegawa D, Kosaka Y, Sano K, Igarashi N, Maruhashi K, Ichimi R, Kawasaki H, Maeda N, Tanizawa A, Arai K, Abe T, Hisakawa H, Miyashita H, Henter JI. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. <span><span class="ref-journal">Blood. </span>1999;<span class="ref-vol">93</span>:1869–74.</span> [<a href="/pubmed/10068659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10068659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.imashuku.2000.37">Imashuku S, Tabata Y, Teramura T, Hibi S. Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). <span><span class="ref-journal">Leuk Lymphoma. </span>2000 Sep;<span class="ref-vol">39</span>:37–49.</span> [<a href="/pubmed/10975382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10975382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.imashuku.2005.315">Imashuku S, Ueda I, Teramura T, Mori K, Morimoto A, Sako M, Ishii E. Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age: analysis of 96 patients. <span><span class="ref-journal">Eur J Pediatr. </span>2005;<span class="ref-vol">164</span>:315–9.</span> [<a href="/pubmed/15731905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15731905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.ishii.2005.3442">Ishii E, Ueda I, Shirakawa R, Yamamoto K, Horiuchi H, Ohga S, Furuno K, Morimoto A, Imayoshi M, Ogata Y, Zaitsu M, Sako M, Koike K, Sakata A, Takada H, Hara T, Imashuku S, Sasazuki T, Yasukawa M. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:3442–8.</span> [<a href="/pubmed/15632205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15632205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.janka.1998.435">Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>1998 Apr;<span class="ref-vol">12</span>:435–44.</span> [<a href="/pubmed/9561911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9561911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.johnson.2010">Johnson J, Kissell D, Huizenga K, Filipovich A, Jordan M, Zur Stadt U, Zhang K. STXBP2 (Munc18) mutations in North American patients with familial hemophagocytic lymphohistiocytosis. Abstract. Montr&#x000e9;al, Quebec, Canada: ASPHO 23rd Annual Meeting, 2010.</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.jordan.2011.4041">Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:4041–52.</span> [<a href="/pmc/articles/PMC3204727/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3204727</span></a>] [<a href="/pubmed/21828139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21828139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.kapelari.2005.619">Kapelari K, Fruehwirth M, Heitger A, K&#x000f6;nigsrainer A, Margreiter R, Simma B, Offner FA. Loss of intrahepatic bile ducts: an important feature of familial hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Virchows Arch. </span>2005;<span class="ref-vol">446</span>:619–25.</span> [<a href="/pubmed/15906086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15906086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.kardas.2012.191">Kardas F, Patiroglu T, Unal E, Chiang SC, Bryceson YT, Kendirci M. Hemophagocytic syndrome in a 4-month-old infant with biotinidase deficiency. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2012 Jul 15;<span class="ref-vol">59</span>:191–3.</span> [<a href="/pubmed/22605457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22605457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.katano.2004.1244">Katano H, Ali MA, Patera AC, Catalfamo M, Jaffe ES, Kimura H, Dale JK, Straus SE, Cohen JI. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:1244–52.</span> [<a href="/pubmed/14576041" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14576041</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.lee.2006.134">Lee SM, Sumegi J, Villanueva J, Tabata Y, Zhang K, Chakraborty R, Sheng X, Clementi R, de Saint Basile G, Filipovich AH. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. <span><span class="ref-journal">J Pediatr. </span>2006;<span class="ref-vol">149</span>:134–7.</span> [<a href="/pubmed/16860143" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16860143</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.ma.2001.358">Ma X, Okamura A, Yosioka M, Ishiguro N, Kikuta H, Kobayashi K. No mutations of SAP/SH2D1A/DSHP and perforin genes in patients with Epstein-Barr virus-associated hemophagocytic syndrome in Japan. <span><span class="ref-journal">J Med Virol. </span>2001;<span class="ref-vol">65</span>:358–61.</span> [<a href="/pubmed/11536244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11536244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.malloy.2004.458">Malloy CA, Polinski C, Alkan S, Manera R, Challapalli M. Hemophagocytic lymphohistiocytosis presenting with nonimmune hydrops fetalis. <span><span class="ref-journal">J Perinatol. </span>2004;<span class="ref-vol">24</span>:458–60.</span> [<a href="/pubmed/15224121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15224121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.marcenaro.2006.2316">Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Aric&#x000f3; M, Moretta L, Pende D. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">108</span>:2316–23.</span> [<a href="/pubmed/16778144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16778144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.marcoux.2005.160">Marcoux MO, Laporte-Turpin E, Alberge C, Fournie-Gardini E, Castex MP, Rolland M, Brivet M, Broue P. Congenital galactosaemia: an unusual presentation. <span><span class="ref-journal">Arch Pediatr. </span>2005;<span class="ref-vol">12</span>:160–2.</span> [<a href="/pubmed/15694540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15694540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.marsh.2010a.1079">Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. <span><span class="ref-journal">Blood. </span>2010a;<span class="ref-vol">116</span>:1079–82.</span> [<a href="/pmc/articles/PMC2938130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2938130</span></a>] [<a href="/pubmed/20489057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20489057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.marsh.2010b.134">Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2010b;<span class="ref-vol">55</span>:134–40.</span> [<a href="/pubmed/20486178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20486178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.marsh.2010c.5824">Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. <span><span class="ref-journal">Blood. </span>2010c;<span class="ref-vol">116</span>:5824–31.</span> [<a href="/pubmed/20855862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20855862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.meeths.2010a.563">Meeths M, Bryceson YT, Rudd E, Zheng C, Wood SM, Ramme K, Beutel K, Hasle H, Heilmann C, Hultenby K, Ljunggren HG, Fadeel B, Nordenskj&#x000f6;ld M, Henter JI. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2010a;<span class="ref-vol">54</span>:563–72.</span> [<a href="/pubmed/19953648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19953648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.meeths.2010b.2635">Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, Almazan F, Boelens JJ, Hasle H, Ifversen M, Lund B, van den Berg JM, Gustafsson B, Hjelmqvist H, Nordenskj&#x000f6;ld M, Bryceson YT, Henter JI. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. <span><span class="ref-journal">Blood. </span>2010b;<span class="ref-vol">116</span>:2635–43.</span> [<a href="/pubmed/20558610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20558610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.meeths.2011.5783">Meeths M, Chiang SC, Wood SM, Entesarian M, Schlums H, Bang B, Nordenskj&#x000f6;ld E, Bj&#x000f6;rklund C, Jakovljevic G, Jazbec J, Hasle H, Holmqvist BM, Rajic L, Pfeifer S, Rosth&#x000f8;j S, Sabel M, Salmi TT, Stokland T, Winiarski J, Ljunggren HG, Fadeel B, Nordenskj&#x000f6;ld M, Henter JI, Bryceson YT. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:5783–93.</span> [<a href="/pubmed/21931115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21931115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.m_nager.2007.473">M&#x000e9;nager M, de Saint Basile G. Secretory cytotoxic granule maturation is required to their lytic contents excretion. <span><span class="ref-journal">Med Sci (Paris). </span>2007;<span class="ref-vol">23</span>:473–4.</span> [<a href="/pubmed/17502060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17502060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.m_nager.2007.257">M&#x000e9;nager MM, M&#x000e9;nasch&#x000e9; G, Romao M, Knapnougel P, Ho CH, Garfa M, Raposo G, Feldmann J, Fischer A, de Saint Basile G. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. <span><span class="ref-journal">Nat Immunol. </span>2007;<span class="ref-vol">8</span>:257–67.</span> [<a href="/pubmed/17237785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17237785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.m_nasch_.2005.165">M&#x000e9;nasch&#x000e9; G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. <span><span class="ref-journal">Immunol Rev. </span>2005;<span class="ref-vol">203</span>:165–79.</span> [<a href="/pubmed/15661029" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15661029</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.m_nasch_.2000.173">M&#x000e9;nasch&#x000e9; G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F, de Saint Basile G. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">25</span>:173–6.</span> [<a href="/pubmed/10835631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10835631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.molleran_lee.2004.137">Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, Filipovich AH. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:137–44.</span> [<a href="/pmc/articles/PMC1735659/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735659</span></a>] [<a href="/pubmed/14757862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14757862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.muiesan.1998.794">Muiesan P, Dhawan A, Wendon J, Mufti GJ, O'Grady J, Rela M, Heaton ND. Hemophagocytosis: a potential complication in small bowel transplantation. <span><span class="ref-journal">Transplantation. </span>1998;<span class="ref-vol">66</span>:794–6.</span> [<a href="/pubmed/9771844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9771844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.neeft.2005.731">Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, Griffith J, Krijgsveld J, Wulffraat N, Koch H, Heck AJ, Brose N, Kleijmeer M, van der Sluijs P. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. <span><span class="ref-journal">Mol Biol Cell. </span>2005;<span class="ref-vol">16</span>:731–41.</span> [<a href="/pmc/articles/PMC545907/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC545907</span></a>] [<a href="/pubmed/15548590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15548590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.nitta.2007.98">Nitta A, Suzumura H, Watabe Y, Okuya M, Nakajima D, Kurosawa H, Sugita K, Arisaka O. Fetal hemophagocytic lymphohistiocytosis in a premature infant. <span><span class="ref-journal">J Pediatr. </span>2007;<span class="ref-vol">151</span>:98.</span> [<a href="/pubmed/17586201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17586201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.normand.2000.5406">Normand NJ, Lehman TJA, Elkon KB, Onel KB. Lower expression of perforin in CD8+ T cells of patients with systemic onset juvenile rheumatoid arthritis. <span><span class="ref-journal">Arthritis Rheum. </span>2000;<span class="ref-vol">43</span>:5406.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.ohadi.1999.165">Ohadi M, Lalloz MR, Sham P, Zhao J, Dearlove AM, Shiach C, Kinsey S, Rhodes M, Layton DM. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:165–71.</span> [<a href="/pmc/articles/PMC1377714/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377714</span></a>] [<a href="/pubmed/9915955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9915955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.orilieri.2008.1078">Orilieri E, Cappellano G, Clementi R, Cometa A, Ferretti M, Cerutti E, Cadario F, Martinetti M, Larizza D, Calcaterra V, D'Annunzio G, Lorini R, Cerutti F, Bruno G, Chiocchetti A, Dianzani U. Variations of the perforin gene in patients with type 1 diabetes. <span><span class="ref-journal">Diabetes. </span>2008;<span class="ref-vol">57</span>:1078–83.</span> [<a href="/pubmed/18198357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18198357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, Kanegane H, Lopez-Granados E, Mejstrikova E, Pellier I, Galicier L, Galambrun C, Barlogis V, Bordigoni P, Fourmaintraux A, Hamidou M, Dabadie A, Le Deist F, Haerynck F, Ouach&#x000e9;e-Chardin M, Rohrlich P, Stephan JL, Lenoir C, Rigaud S, Lambert N, Milili M, Schiff C, Chapel H, Picard C, de Saint Basile G, Blanche S, Fischer A, Latour S. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:1522–9.</span> [<a href="/pubmed/21119115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21119115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.pagel.2012.6016">Pagel J, Beutel K, Lehmberg K, Koch F, Maul-Pavicic A, Rohlfs AK, Al-Jefri A, Beier R, Bomme Ousager L, Ehlert K, Gross-Wieltsch U, Jorch N, Kremens B, Pekrun A, Sparber-Sauer M, Mejstrikova E, Wawer A, Ehl S, zur Stadt U, Janka G. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">119</span>:6016–24.</span> [<a href="/pubmed/22451424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22451424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.rigaud.2006.110">Rigaud S, Fondan&#x000e8;che MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint Basile G, Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">444</span>:110–4.</span> [<a href="/pubmed/17080092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17080092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.rudd.2006.e14">Rudd E, G&#x000f6;ransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, G&#x000fc;rgey A, Fadeel B, Nordenskj&#x000f6;ld M, Henter JI. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:e14.</span> [<a href="/pmc/articles/PMC2563216/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563216</span></a>] [<a href="/pubmed/16582076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16582076</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.shah.2009.139">Shah AJ, Kapoor N, Cooper RM, Crooks GM, Lenarsky C, Abdel-Azim H, Wu SQ, Wilson K, Weinberg KI, Parkman R, Kohn DB. Pre- and post-natal treatment of hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2009;<span class="ref-vol">52</span>:139–42.</span> [<a href="/pmc/articles/PMC2592085/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2592085</span></a>] [<a href="/pubmed/18819128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18819128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.shuper.1998.126">Shuper A, Attias D, Kornreich L, Zaizov R, Yaniv I. Familial hemophagocytic lymphohistiocytosis: improved neurodevelopmental outcome after bone marrow transplantation. <span><span class="ref-journal">J Pediatr. </span>1998;<span class="ref-vol">133</span>:126–8.</span> [<a href="/pubmed/9672524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9672524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.sieni.2012a.29">Sieni E, Cetica V, Mastrodicasa E, Pende D, Moretta L, Griffiths G, Aric&#x000f2; M. Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity. <span><span class="ref-journal">Cell Mol Life Sci. </span>2012a;<span class="ref-vol">69</span>:29–40.</span> [<a href="/pubmed/21990010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21990010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.sieni.2012b.e44649">Sieni E, Cetica V, Piccin A, Gherlinzoni F, Sasso FC, Rabusin M, Attard L, Bosi A, Pende D, Moretta L, Aric&#x000f2; M. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. <span><span class="ref-journal">PLoS One. </span>2012b;<span class="ref-vol">7</span>:e44649.</span> [<a href="/pmc/articles/PMC3436758/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3436758</span></a>] [<a href="/pubmed/22970278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22970278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.solomou.2007.5234">Solomou EE, Gibellini F, Stewart B, Malide D, Berg M, Visconte V, Green S, Childs R, Chanock SJ, Young NS. Perforin gene mutations in patients with acquired aplastic anemia. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:5234–7.</span> [<a href="/pmc/articles/PMC1890825/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1890825</span></a>] [<a href="/pubmed/17311987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17311987</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.st_phan.1993.451">St&#x000e9;phan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. <span><span class="ref-journal">Clin Exp Rheumatol. </span>1993;<span class="ref-vol">11</span>:451–6.</span> [<a href="/pubmed/8403593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8403593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.stepp.1999.1957">Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Science. </span>1999;<span class="ref-vol">286</span>:1957–9.</span> [<a href="/pubmed/10583959" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10583959</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.sung.2002.550">Sung L, King SM, Carcao M, Trebo M, Weitzman SS. Adverse outcomes in primary hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2002;<span class="ref-vol">24</span>:550–4.</span> [<a href="/pubmed/12368693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12368693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.trambas.2005.932">Trambas C, Gallo F, Pende D, Marcenaro S, Moretta L, De Fusco C, Santoro A, Notarangelo L, Arico M, Griffiths GM. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:932–7.</span> [<a href="/pubmed/15741215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15741215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.trizzino.2008.15">Trizzino A, zur Stadt U, Ueda I, Risma K, Janka G, Ishii E, Beutel K, Sumegi J, Cannella S, Pende D, Mian A, Henter JI, Griffiths G, Santoro A, Filipovich A, Aric&#x000f2; M., Histiocyte Society HLH Study group.  Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. <span><span class="ref-journal">J Med Genet. </span>2008;<span class="ref-vol">45</span>:15–21.</span> [<a href="/pubmed/17873118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17873118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.ueda.2006.179">Ueda H, Kashiwamura S, Sekiyama A, Ogura T, Gamachi N, Okamura H. Production of IL-13 in spleen cells by IL-18 and IL-12 through generation of NK-like cells. <span><span class="ref-journal">Cytokine. </span>2006;<span class="ref-vol">33</span>:179–87.</span> [<a href="/pubmed/16549365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16549365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.villanueva.2005.r30">Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. <span><span class="ref-journal">Arthritis Res Ther. </span>2005;<span class="ref-vol">7</span>:R30–7.</span> [<a href="/pmc/articles/PMC1064882/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1064882</span></a>] [<a href="/pubmed/15642140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15642140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.voskoboinik.2007.1184">Voskoboinik I, Sutton VR, Ciccone A, House CM, Chia J, Darcy PK, Yagita H, Trapani JA. Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:1184–90.</span> [<a href="/pubmed/17475905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17475905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.voskoboinik.2004.811">Voskoboinik I, Thia MC, De Bono A, Browne K, Cretney E, Jackson JT, Darcy PK, Jane SM, Smyth MJ, Trapani JA. The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene. <span><span class="ref-journal">J Exp Med. </span>2004;<span class="ref-vol">200</span>:811–6.</span> [<a href="/pmc/articles/PMC2211966/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2211966</span></a>] [<a href="/pubmed/15365097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15365097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.voskoboinik.2005.4700">Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:4700–6.</span> [<a href="/pubmed/15755897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15755897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.woods.2009.265">Woods CW, Bradshaw WT, Woods AG. Hemophagocytic lymphohistiocytosis in the premature neonate. <span><span class="ref-journal">Adv Neonatal Care. </span>2009;<span class="ref-vol">9</span>:265–73.</span> [<a href="/pubmed/20010142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20010142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.yamamoto.2004.763">Yamamoto K, Ishii E, Sako M, Ohga S, Furuno K, Suzuki N, Ueda I, Imayoshi M, Yamamoto S, Morimoto A, Takada H, Hara T, Imashuku S, Sasazuki T, Yasukawa M. Identification of novel MUNC13-4 mutations in familial haemophagocytic lymphohistiocytosis and functional analysis of MUNC13-4-deficient cytotoxic T lymphocytes. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:763–7.</span> [<a href="/pmc/articles/PMC1735600/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735600</span></a>] [<a href="/pubmed/15466010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15466010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.zhang.2011.5794">Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:5794–8.</span> [<a href="/pmc/articles/PMC3228496/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3228496</span></a>] [<a href="/pubmed/21881043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21881043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.zhang.2008.2892">Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. <span><span class="ref-journal">Arthritis Rheum. </span>2008;<span class="ref-vol">58</span>:2892–6.</span> [<a href="/pmc/articles/PMC2779064/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2779064</span></a>] [<a href="/pubmed/18759271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18759271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.zhang.2007.231">Zhang K, Johnson JA, Biroschak J, Villanueva J, Lee SM, Bleesing JJ, Risma KA, Wenstrup RJ, Filipovich AH. Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects. <span><span class="ref-journal">Int J Immunogenet. </span>2007;<span class="ref-vol">34</span>:231–3.</span> [<a href="/pubmed/17627755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17627755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.ziegler.1996.19">Ziegler SF, Mortrud MT, Swartz AR, Baker E, Sutherland GR, Burmeister M, Mulligan JT. Molecular characterization of a nonneuronal human UNC18 homolog. <span><span class="ref-journal">Genomics. </span>1996;<span class="ref-vol">37</span>:19–23.</span> [<a href="/pubmed/8921365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8921365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.zur_stadt.2006.62">zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies HC. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:62–8.</span> [<a href="/pubmed/16278825" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16278825</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.zur_stadt.2009.482">zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, Strauss J, Kasper B, N&#x000fc;rnberg G, Becker C, Maul-Pavicic A, Beutel K, Janka G, Griffiths G, Ehl S, Hennies HC. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">85</span>:482–92.</span> [<a href="/pmc/articles/PMC2756548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2756548</span></a>] [<a href="/pubmed/19804848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19804848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlh.REF.zur_stadt.2005.827">zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, Kabisch H, Schneppenheim R, N&#x000fc;rnberg P, Janka G, Hennies HC. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:827–34.</span> [<a href="/pubmed/15703195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15703195</span></a>]</div></li></ul></div></div><div id="hlh.Chapter_Notes"><h2 id="_hlh_Chapter_Notes_">Chapter Notes</h2><div id="hlh.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 January 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 September 2010 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>STXBP2</i> for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis 5 available clinically</div></li><li class="half_rhythm"><div>11 March 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 March 2007 (cd) Revision: clinical testing and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available for FHL4</div></li><li class="half_rhythm"><div>22 March 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>21 April 2005 (jj, af, rw) Original Submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1444</span><span class="label">PMID: <a href="/pubmed/20301617" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301617</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hartsfield/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hemo-a/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1444&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1444/?report=reader">PubReader</a></li><li><a href="/books/NBK1444/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1444" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1444" style="display:none" title="Cite this Page"><div class="bk_tt">Zhang K, Filipovich AH, Johnson J, et al. Hemophagocytic Lymphohistiocytosis, Familial. 2006 Mar 22 [Updated 2013 Jan 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1444/pdf/Bookshelf_NBK1444.pdf">PDF version of this page</a> (558K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=201294[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">UNC13D</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6813[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">STXBP2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5551[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PRF1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8676[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">STX11</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16278825" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A.</a><span class="source">[Hum Mutat. 2006]</span><div class="brieflinkpop offscreen_noflow">Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies HC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mutat. 2006 Jan; 27(1):62-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19884660" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.</a><span class="source">[J Clin Invest. 2009]</span><div class="brieflinkpop offscreen_noflow">Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Côte M, Ménager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, Al-Manjomi F, Al-Harbi M, Alangari A, Le Deist F, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Invest. 2009 Dec; 119(12):3765-73. Epub 2009 Nov 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21152410" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Subtypes of familial hemophagocytic lymphohistiocytosis in Japan based on genetic and functional analyses of cytotoxic T lymphocytes.</a><span class="source">[PLoS One. 2010]</span><div class="brieflinkpop offscreen_noflow">Subtypes of familial hemophagocytic lymphohistiocytosis in Japan based on genetic and functional analyses of cytotoxic T lymphocytes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nagai K, Yamamoto K, Fujiwara H, An J, Ochi T, Suemori K, Yasumi T, Tauchi H, Koh K, Sato M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PLoS One. 2010 Nov 30; 5(11):e14173. Epub 2010 Nov 30.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301580" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lymphoproliferative Disease, X-Linked</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lymphoproliferative Disease, X-Linked<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang K, Wakefield E, Marsh R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301617" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301617" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0429addde0891169a290aa">Hemophagocytic Lymphohistiocytosis, Familial - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hemophagocytic Lymphohistiocytosis, Familial - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:31:57-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CA31DE0423FD100000000026E00F5&amp;ncbi_session=CE8CA31DE0429AC1_0622SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1444%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1444&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1444/&amp;ncbi_pagename=Hemophagocytic Lymphohistiocytosis, Familial - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CA31DE0429AC1_0622SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>